Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 66
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Scheeren Brum, Wagner|||0000-0002-9777-0559
  • Molfetta, Guglielmo Di
  • Benedet, Andréa Lessa
  • Arslan, Burak
  • Jonaitis, Erin Mc Mullen
  • Langhough, Rebecca E.
  • Cody, Karly Alex
  • Wilson, Rachael E.
  • Carlsson, Cynthia M.
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Rahmouni, Nesrine
  • Tissot, Cécile
  • Stevenson, Jenna
  • Servaes, Stijn|||0000-0002-4431-957X
  • Therriault, Joseph
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Johnson, Sterling C.
  • Jeromin, Andreas
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
IMPORTANCE Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Alzheimer Dementia Among Individuals With Down Syndrome

  • Rubenstein, Eric
  • Tewolde, Salina
  • Michals, Amy
  • Weuve, Jennifer
  • Fortea, Juan|||0000-0002-1340-638X
  • Fox, Matthew P.
  • Pescador Jimenez, Marcia
  • Scott, Ashley
  • Tripodis, Yorghos
  • Skotko, Brian G.
What is the incidence and prevalence of Alzheimer dementia in patients with Down syndrome using data from the US Medicare and Medicaid? In this cohort study of 132 720 adults with Down syndrome enrolled in Medicaid or Medicare between 2011 to 2019, 23.3% of adults had Alzheimer dementia diagnoses, and the mean age of death was 59.2 years. These findings suggest that Alzheimer dementia is almost universal among people with Down syndrome, and administrative claims data may offer valuable insights into improving care for this diverse population. This cohort study examines the prevalence and incidence of Alzheimer disease among individuals with Down syndrome using US Medicare and Medicaid claims data. With the advancement in administrative data as a research tool and the reliance on public health insurance for individuals with Down syndrome, population-level trends in Alzheimer dementia in this population are beginning to be understood. To comprehensively describe the epidemiology of Alzheimer dementia in adults with Down syndrome in a full US Medicare and Medicaid sample. This cohort study included 132 720 adults aged 18 years or older with Medicaid and/or Medicare claims data with an International Statistical Classification of Diseases and Related Health Problems code for Down syndrome. Data were collected from January 1, 2011, to December 31, 2019, and analyzed from August 2023 to May 2024. The main outcome was prevalence of Alzheimer dementia in each calendar year and during the 9-year period. Alzheimer dementia incidence rates by calendar year and age and stratified for race or ethnicity as well as time to death after Alzheimer dementia diagnosis were also assessed. There were 132 720 unique adults with Down syndrome from 2011 to 2019: 79 578 (53.2%) were male, 17 090 (11.7%) were non-Hispanic Black, 20 777 (15.7%) were Hispanic, 101 120 (68.8%) were non-Hispanic White, and 47 692 (23.3%) had ever had an Alzheimer dementia diagnosis. Incidence was 22.4 cases per 1000 person-years. The probability of an incident Alzheimer dementia diagnosis over 8 years was 0.63 (95% CI, 0.62-0.64) for those entering the study between ages 55 to 64 years. Mean (SD) age at incident diagnosis was 54.5 (7.4) years and median (IQR) age was 54.6 (9.3) years. Mean (SD) age at death among those with Alzheimer dementia was 59.2 (6.9) years (median [IQR], 59.0 [8.0] years). The mean (SD) age at onset for the Hispanic group was 54.2 (9.2) years, 52.4 (7.8) years for the American Indian or Alaska Native group, and 52.8 (8.2) years for the mixed race groups compared with 55.0 (7.8) years for the White non-Hispanic group. For age at death, there were no differences by sex. The mean (SD) age at death was later for the White non-Hispanic group (59.3 [6.8] years) compared with the Hispanic group (58.5 [7.8] years), Native American group (57.8 [7.1] years), and mixed race group (58.2 [7.0] years). In this cohort study of adults with Down syndrome who were enrolled in Medicaid and Medicare, Alzheimer dementia occurred at high rates. Consistency with clinical studies of dementia in Down syndrome supports the use of administrative data in Down syndrome-Alzheimer dementia research.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's disease

  • Kac, Przemysław R.|||0000-0001-5083-0924
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Fernández, Susana|||0000-0002-9777-1156
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • González-Ortiz, Fernando
  • Benejam, Bessy|||0000-0002-6789-8615
  • Turton, Michael
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Harrison, Peter
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Fortea, Juan|||0000-0002-1340-638X
  • Blennow, Kaj|||0000-0002-1890-4193
All individuals with Down Syndrome (DS) will develop full-blown Alzheimeŕs disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation between age and AD pathology risk in DS is important to accelerate diagnostics, disease monitoring, and treatment. Several genes encoded in chromosome 21 including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) have been proven to contribute to the pathology. A recently validated plasma immunoassay to measure tau phosphorylation at threonine-212 (p-tau212) has very high diagnostic accuracy in detecting AD. P-tau212 is also very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD. Using Simoa technology, we tested p-tau212 and p-tau181 (n=245 for plasma, n=114 matching cerebrospinal fluid (CSF) samples). We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the AUC-ROC differences between methods. Spearman correlation is used to examine correlations. Fold changes relative to median levels were calculated for their respective asymptomatic groups. ANCOVA followed by Tukey posthoc test was used to calculate differences across groups. LOESS was used to determine the temporality of plasma biomarker changes. We have confirmed that p-tau212 has extremely high accuracy in detecting AD-related changes in euploid controls. For the DS population, we observed a strong correlation between plasma and CSF p-tau212 (r=0.867; p<0.001). In prodromal DS (pDS) and dementia DS (dDS), we observed significantly elevated levels of p-tau212 in reference to asymptomatic DS (aDS). The diagnostic accuracy to differentiate between aDS and dDS was AUC=0.91 and AUC = 0.86 in discriminating between DS amyloid positive and amyloid negative participants. Plasma p-tau212 started increasing approximately when people became amyloid PET-positive. We have confirmed that the levels of plasma p-tau212 are increased in the DS population and sporadic AD cases including prodromal and MCI states. Plasma p-tau212 might have utility for theragnostic, monitoring therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bridging perspectives, The value of collaboration between Traditional Healing Practitioners and Medical Doctors in dementia research and care in South Africa

  • McGlinchey, E.
  • Ranchod, K.
  • Stroebel, R.
  • Lusizi, B.
  • Galvin, M.
  • Kleinhans, A.V.
  • Fortea, Juan|||0000-0002-1340-638X
  • Hoffman, J.
  • Makanya, S.
INTRODUCTION: Traditional Healing Practitioners (THPs) provide care to the majority of the population in South Africa. Despite their widespread presence, they remain largely excluded from dementia research and policy. This reinforces healthcare inequities and overlooks the realities of communities where THPs provide care. METHODS: This paper explores the role of THPs in dementia care by examining literature in South Africa. It identifies key barriers to collaboration between THPs and medical doctors and discusses pathways for integration. RESULTS: Barriers include epistemological historical marginalization, mutual distrust, fragmented care pathways, and language barriers. These challenges hinder knowledge exchange and joint dementia care strategies. DISCUSSION: Strengthening relationships through structured engagement, bidirectional knowledge exchange, and ethical collaboration could bridge the gap between THPs and Medical Doctors (MDs). A pluralistic, integrated model valuing both systems could lead to more equitable and effective dementia care. Highlights: The majority of people in South Africa engage with Traditional Healing Practitioners (THPs) as part of their healthcare, yet THPs remain largely excluded from dementia research and policy. Barriers to collaboration between THPs and Medical Doctors (MDs) include historical marginalization, mutual distrust, fragmented care pathways, and language differences. Integrating THPs and MDs through structured engagement, bidirectional knowledge exchange, and ethical collaboration could enhance dementia care. Shifting away from the binary opposition of Indigenous Knowledge Systems (IKS) and biomedical approaches toward a more integrated and collaborative model of dementia care could lead to more equitable and effective healthcare. The FUNDISA (Framework for Understanding Neurocognitive Disorders via Indigenous Systems in South Africa) project aims to understand how dementia is conceptualized by THPs and foster collaboration between THPs and MDs to support effective dementia care.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Discrepancies in assessing intellectual disability levels in adults with Down syndrome, Implications for dementia diagnosis

  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Wlasich, E.
  • Kustermann, J.
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fernández, Susana|||0000-0002-9777-1156
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • San Juan, Aida
  • Nübling, G.
  • Wagemann, O.
  • Stockbauer, A.
  • Hassenstab, J.
  • Levin, J.
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Cut-offs derived from baseline cognitive assessments, stratified by intellectual disability (ID) level, have been proposed to diagnose symptomatic Alzheimer's disease (AD) in Down syndrome (DS). However, discrepancies in ID classification risk misclassification when applying cut-offs across sites. METHODS: This dual-center cohort study included 673 adults with mild to moderate ID at different AD stages. We assessed ID classification discrepancies across sites and the impact on Cambridge Cognitive Examination for Older Adults with Down's Syndrome (CAMCOG-DS) cut-offs for AD dementia diagnosis derived from receiver operating characteristic analysis. RESULTS: Inter-rater agreement for ID level classification was 95% within sites but 60% between sites. While CAMCOG-DS score distributions in the whole cohort were similar across sites, ID classification discrepancies caused higher cut-offs in Barcelona for mild and moderate ID compared to Munich. Applying site-specific cut-offs to another cohort reduced sensitivity and specificity. DISCUSSION: Standardizing ID classification is critical for generalizable cut-offs to accurately diagnose AD dementia based on neuropsychological assessments in DS. Highlights: CAMCOG-DS cut-offs by intellectual disability level classify dementia in Down syndrome. ID classification discrepancies between sites impact CAMCOG-DS diagnostic cut-offs. Applying site-specific cut-offs to other cohorts reduces sensitivity and specificity. Standardized ID classification is essential for generalizable cognitive cut-offs. Use site-specific cut-offs until ID classification is standardized.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Down syndrome in Africa, Challenges, opportunities, and future directions

  • McGlinchey, E.
  • Tewolde, S.
  • He, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Mbakile-Mahlanza, L.
  • Tefera, A.
  • Epenge, E.
  • Hassenstab, J.
  • Jäck, A.
  • Ranchod, K.
  • El-Jaafary, S.
  • Levin, J.
  • Salama, M.
  • Rubenstein, E.
  • Akinyemi, R.
  • Akinyemi, T.
  • Farombi, T.
  • Lawlor, B.
  • Ikanga, J.
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Stout, S.
  • Balls-Berry, J.
  • Kleinhans, A.V.
  • Maina, R.
  • Merali, Z.
INTRODUCTION: As life expectancy improves for people with Down syndrome (DS) in Africa, the risk of developing DS-associated Alzheimer's disease (DSAD) will rise. There is a pressing need to plan for this emerging challenge, particularly in the context of existing health and social disparities. METHODS: This work emerged from a pan-African collaboration, including discussions at the Brain Ageing and Dementia in Low- and Middle-Income Countries conference held in Nairobi in 2024, where stakeholders identified regional priorities for DS and dementia care. RESULTS: Limited epidemiological, cognitive, biomarker data, delayed diagnoses, and gaps in specialized services may impact access to care. However, innovative solutions, such as mobile biomarker sampling and culturally adapted cognitive assessments, offer promising strategies. DISCUSSION: Integrating global advances in DSAD research with Africa's strengths in community-based care offers opportunities. By prioritizing research, capacity building, and health system integration, this work advocates for the inclusion of DS in Africa's dementia strategies. Highlights: Projected increases in life expectancy for individuals with Down syndrome (DS) in Africa will lead to a substantial rise in DS-associated Alzheimer's disease (DSAD), necessitating urgent planning and response. There is a critical lack of epidemiological, cognitive, and biomarker data on adults with DS in Africa, hindering accurate diagnosis, care planning, and inclusion in global research. Innovative, scalable solutions-such as mobile biomarker sampling and culturally adapted cognitive assessments-offer an opportunity to integrate scientific advances with Africa's strengths in community-based care. Investment in research and capacity building is essential to address current gaps, reduce disparities, and ensure equitable access to emerging diagnostics and treatments for DSAD across the continent.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tuning Covalent Organic Frameworks via Nucleophilic Aromatic Substitution

  • González-Rosell, Óscar|||0009-0009-3439-7636
  • Reyes-Mesa, David|||0009-0009-3838-068X
  • Gallego-Gamo, Albert|||0000-0003-1278-9339
  • Matheu, Roc
  • Molins Grau, Elies|||0000-0003-1012-0551
  • Pleixats, Roser|||0000-0003-2544-732X
  • Vallribera, Adelina|||0000-0002-6452-4589
  • Granados, Albert|||0000-0002-5362-5966
  • Gimbert-Suriñach, Carolina|||0000-0002-4412-7607
A family of covalent organic frameworks (COFs) with tuned properties has been prepared through nucleophilic aromatic substitution (SNAr) from a fluorinated imine-linked COF (COF-F). The method has proved useful for O-, S-, and N-based nucleophiles, including bifunctional molecules, leading to average degrees of substitution (DS) ranging from 34% to 87%. COF-EG, COF-Fc, and COF-Cz containing ethylene glycol (DS = 49%), ferrocene (DS = 23%), or carbazole (DS = 34%) moieties, respectively, have been prepared, showcasing the versatility of the methodology. The introduction of these functional molecules on the framework provides unique properties to the organic material, while maintaining the ordered structure. COF-EG is highly crystalline, porous, and hydrophilic, while COF-Fc shows a broad redox profile characteristic of the ferrocene/ferrocenium couple, which is covalently attached to the hexagonal framework. The optical properties of the new family of compounds are also greatly influenced by the substitution, with COF-Cz featuring a remarkably extended absorption profile beyond 700 nm and an optical bandgap of 1.9 eV, significantly reduced compared to the 2.6 eV of the starting fluorinated COF-F material and the rest of the substituted materials in the range of 2.1-2.5 eV.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

On the weak convergence of multiparameter stochastic integrals

  • Bardina, Xavier|||0000-0003-1803-3401
  • Boukfal, Salim|||0009-0007-5296-7087
In this paper we provide sufficient conditions for sequences of stochastic processes of the form f [0,t] f n(u)θ n(u)du, to weakly converge, in the space of continuous functions over a closed interval, to integrals with respect to the Brownian motion, ∫ [0,t] f(u)W(du), where {fn}n is a sequence of functions converging to f which verify some integrability conditions and { θ n } n is a sequence of stochastic processes whose integrals f [0,t] θ n(u)du converge in law to the Brownian motion (in the sense of the finite dimensional distribution convergence), in the multiparameter case.
Repisalud
Publication Artículo científico (JournalArticle)

Prevalence and factors linked to renal involvement in prediabetes patients across Europe in the ePREDICE trial

  • Más-Fontao, Sebastián
  • Civantos, Esther
  • Boukichou-Abdelkader, Nisa
  • Moreno, Juan A
  • Tuomilehto, Jaakko
  • Gabriel-Sanchez, Rafael
  • Egido, Jesús
This sub-analysis of the ePREDICE trial, investigated the prevalence and determinants of renal complications, specifically glomerular hyperfiltration, albuminuria, and reduced kidney function, in individuals with prediabetes (PD). The cohort consisted of 967 participants from diverse backgrounds across seven countries. The kidney function was evaluated using the MDRD-4 equation, and the influence of various clinical and demographic factors on renal involvement was assessed by multivariable regression models. Additionally, insulinogenic and disposition indices were examined. Overall, the prevalence of renal abnormalities in this PD cohort was 9.2% (n = 89). Key findings included the detection of hyperfiltration in 20 (2%) individuals, albuminuria in 45 (4.7%), and CKD stage G3a in 29 (3%). Hyperfiltration was inversely correlated with age and height, while albuminuria showed a significant direct association with the disposition index (DI). Age and waist circumference were significantly and directly associated with estimated glomerular filtration rate (eGFR). The ePREDICE study highlights critical factors that affect renal involvement in PD individuals, revealing complex interactions among various parameters. These findings further emphasize the necessity for the search of early kidney abnormalities in people with PD especially in those in older age groups and with a large waist circumference.
Repisalud
Publication Artículo científico (JournalArticle)

Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysis

  • Castilla Catalán, Jesús
  • Navascués, Ana
  • Casado, Itziar
  • Díaz-González, Jorge
  • Pérez-García, Alejandra
  • Fernandino, Leticia
  • Martínez-Baz, Iván
  • Aguinaga, Aitziber
  • Pozo Sanchez, Francisco
  • Ezpeleta, Carmen
The 2016/17 mid-season vaccine effectiveness estimate against influenza A(H3N2) was 15% (95% confidence interval: -11 to 35) in Navarre. Comparing to individuals unvaccinated in the current and four prior seasons, effectiveness was 24% for current and 3-4 prior doses, 61% for current and 1-2 prior doses, 42% for only current vaccination, and 58% for 3-4 prior doses. This suggests moderate effectiveness for different combinations of vaccination in the current and prior seasons.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Optimization of the addition of carrot dietary fibre to a dry fermented sausage (sobrassada) using artificial neural networks

  • Eim, Valeria S.
  • Simal Florindo, Susana
  • Rossello Matas, Carmen
  • Femenia Marroig, Antoni
  • Bon Corbín, José|||0000-0002-0457-9705
An optimisation problem was formulated to maximise the amount of carrot dietary fibre (CDF) in a dry fermented sausage, while maintaining product quality, by using 0 12% CDF as the decision variable, and limiting values of several physico-chemical and textural parameters (moisture content, water activity, pH, colour, non-protein nitrogen, free fatty acid, compression work and hardness) as constraints. The evolution of each quality parameter during the ripening process was estimated by developing a multi-layer feed forward artificial neural network (ANN), taking into consideration the CDF concentration and the ripening time as independent variables. Results indicate an optimum CDF concentration of 4.9% with a good correlation between experimental and estimated values (mean relative error &#8804; 3.35%)., The authors would like to acknowledge the financial support of the Spanish Government through the MICINN (DPI2009-14549-C04), from the CARNISENUSA project (CSD2007-00016) included in the programme CONSOLIDER-INGENIO-2010, the Balearic Government and European Regional Development Fund (FEDER) RTA2009-00119-C02-02 (57/2011), and the Balearic Government (Research Fellowship FPI07).
eBiltegia. Repositorio Institucional de Mondragon Unibertsitatea
Publication

MarMot: Metamorphic Runtime Monitoring of Autonomous Driving Systems

  • Ayerdi, Jon Joseba
  • Iriarte, Asier
  • Valle Entrena, Pablo
  • Roman Txopitea, Ibai
  • Illarramendi, Miren
  • Arrieta, Aitor
eBiltegia. Repositorio Institucional de Mondragon Unibertsitatea
Publication Artículo científico (JournalArticle)

GenMorph: Automatically Generating Metamorphic Relations via Genetic Programming

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study

  • Rodríguez-Fernández, Blanca
  • Vilor-Tejedor, Natalia
  • Arenaza-Urquijo, Eider M.
  • Sánchez-Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Operto, Grégory
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Suridjan, Ivonne
  • Castro de Moura, Manuel
  • Piñeyro, David
  • Esteller, Manel
  • Blennow, Kaj
  • Zetterberg, Henrik
  • De Vivo, Immaculata
  • Molinuevo, José Luis
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Sala-Vila, Aleix
  • Crous-Bou, Marta
  • ALFA study
Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer’s disease (AD). We aimed to evaluate the potential causal role of TL in AD endophenotypes (i.e., cognitive performance, N = 2233; brain age and AD-related signatures, N = 1134; and cerebrospinal fluid biomarkers (CSF) of AD and neurodegeneration, N = 304) through a Mendelian randomization (MR) analysis. Our analysis was conducted in the context of the ALFA (ALzheimer and FAmilies) study, a population of cognitively healthy individuals at risk of AD. A total of 20 single nucleotide polymorphisms associated with TL were used to determine the effect of TL on AD endophenotypes. Analyses were adjusted by age, sex, and years of education. Stratified analyses by APOE-ɛ4 status and polygenic risk score of AD were conducted. MR analysis revealed significant associations between genetically predicted longer TL and lower levels of CSF Aβ and higher levels of CSF NfL only in APOE-ɛ4 non-carriers. Moreover, inheriting longer TL was associated with greater cortical thickness in age and AD-related brain signatures and lower levels of CSF p-tau among individuals at a high genetic predisposition to AD. Further observational analyses are warranted to better understand these associations., The project leading to these results has received funding from the Alzheimer’s Association (Grant AARG-19-618265). This project has received funding from Instituto de Salud Carlos III (PI19/00119). Additional support has been received from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007), the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T is funded by a post-doctoral grant, Juan de la Cierva Incorporación Programme (IJC2020-043216-I), Ministry of Science and Innovation–Spanish State Research Agency. EMAU is supported by the Spanish Ministry of Science, Innovation and Universities - Spanish State Research Agency (RYC2018-026053-I). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement no. 948677). MS-C also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). AS-V. is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antifibrotic Agents for the Management of CKD: A Review

  • Ruiz-Ortega, Marta
  • Lamas Peláez, Santiago
  • Ortiz, Alberto
Kidney fibrosis is a hallmark of chronic kidney disease (CKD) and a potential therapeutic target. However, there are conceptual and practical challenges to directly targeting kidney fibrosis. Whether fibrosis is mainly a cause or a consequence of CKD progression has been disputed. It is unclear whether specifically targeting fibrosis is feasible in clinical practice because most drugs that decrease fibrosis in preclinical models target additional and often multiple pathogenic pathways (eg, renin-angiotensin-aldosterone system blockade). Moreover, tools to assess whole-kidney fibrosis in routine clinical practice are lacking. Pirfenidone, a drug used for idiopathic pulmonary fibrosis, is undergoing a phase 2 trial for kidney fibrosis. Other drugs in use or being tested for idiopathic pulmonary fibrosis (eg, nintedanib, PRM-151, epigallocatechin gallate) are also potential candidates to treat kidney fibrosis. Novel therapeutic approaches may include antagomirs (eg, lademirsen) or drugs targeting interleukin 11 or NKD2 (WNT signaling pathway inhibitor). Reversing the dysfunctional tubular cell metabolism that leads to kidney fibrosis offers additional therapeutic opportunities. However, any future drug targeting fibrosis of the kidneys should demonstrate added benefit to a standard of care that combines renin-angiotensin system with mineralocorticoid receptor (eg, finerenone) blockade or with sodium/glucose cotransporter 2 inhibitors., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119, PI20/00140, DTS20/00083, PI18/01366, PI19/00588, PI19/00815, DTS18/00032, Red de Investigacion Renal REDINREN: RD16/0009, RICORS2040 RD21/0005/0001) Comunidad Autonoma de Madrid FEDER-a way to build Europe (B2017/ BMD-3751 NOVELREN-CM to MR-O and SL); Convocatoria Dinamizacion Europa Investigacion 2019 ” MINECO (EIN2019-103294 to M.R-O B2017/BMD-3686 CIFRA2-CM to AO); Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMPROVE-PD ID: 812699) to MR-O; and ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, Sociedad Espanola de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina and Ministerio de Ciencia e Innovación: PID2019-104233RB-I00/AEI/10.13039/501100011033 to SL
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice

  • Opazo-Ríos, Lucas
  • Tejera-Muñoz, Antonio
  • Soto Catalan, Manuel
  • Marchant, Vanessa
  • Mas Fontao, Sebastián
  • Lavoz, Carolina
  • Moreno, Juan Antonio
  • Fierro Fernandez, Marta
  • Ramos, Ricardo
  • Suarez-Alvarez, Beatriz
  • López-Larrea, Carlos
  • Ruiz-Ortega, Marta
  • Egido, Jesús
  • Rodrigues-Díez, Raúl R.
Diabetic nephropathy (DN) is the main leading cause of chronic kidney disease worldwide. Although remarkable therapeutic advances have been made during the last few years, there still exists a high residual risk of disease progression to end-stage renal failure. To further understand the pathogenesis of tissue injury in this disease, by means of the Next-Generation Sequencing, we have studied the microRNA (miRNA) differential expression pattern in kidneys of Black and Tan Brachyury (BTBR) ob/ob (leptin deficiency mutation) mouse. This experimental model of type 2 diabetes and obesity recapitulates the key histopathological features described in advanced human DN and therefore can provide potential useful translational information. The miRNA-seq analysis, performed in the renal cortex of 22-week-old BTBR ob/ob mice, pointed out a set of 99 miRNAs significantly increased compared to non-diabetic, non-obese control mice of the same age, whereas no miRNAs were significantly decreased. Among them, miR-802, miR-34a, miR-132, miR-101a, and mir-379 were the most upregulated ones in diabetic kidneys. The in silico prediction of potential targets for the 99 miRNAs highlighted inflammatory and immune processes, as the most relevant pathways, emphasizing the importance of inflammation in the pathogenesis of kidney damage associated to diabetes. Other identified top canonical pathways were adipogenesis (related with ectopic fatty accumulation), necroptosis (an inflammatory and regulated form of cell death), and epithelial-to-mesenchymal transition, the latter supporting the importance of tubular cell phenotype changes in the pathogenesis of DN. These findings could facilitate a better understanding of this complex disease and potentially open new avenues for the design of novel therapeutic approaches to DN., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/ 00119, PI17/01495, PI17/00130, PI20/00140, PI19/00184, PI20/00639, PI20/00487, PI20/00375, DTS20/00083, and DTS19/00093), Red de Investigación Renal REDINREN: RD16/0009 to MR-O (RD16/0009/0003) and to CL-L (RD16/0009/0020), Sociedad Española de Nefrología, “NOVELREN-CM: Enfermedad renal crónica: nuevas Estrategias para la prevención, Diagnóstico y tratamiento” (B2017/BMD-3751 to MR-O), “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN 2019-103294 to MR-O), Innovation programme under the Marie SkłodowskaCurie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699 to MR-O), Spanish Biomedical Research Centre in Cardiovascular Diseases (CIBERCV), Spanish Ministry of Science and Innovation (RYC-2017- 22369), Consejería de Salud y Familias-FEDER, Junta de Andalucía (PIGE-0052-2020 to JM), and Gobierno de Chile (S-2020-05 VIDCA-UACh to CL). RICORS program to RICORS2040 (KIDNEY DISEASE) RD21/0005/0002 to MRO; RD21/0005/0017 to CL-L.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

On the presence of an unexpected meadow of Penicillus capitatus Lamarck (Bryopsidales: Chlorophyta) in Mallorca, Balearic Islands, Western Mediterranean

  • Hierro, Andrea
  • Ballesteros, Enric
  • Máñez-Crespo, Julia
  • Reynés, Xesca
  • Tomàs, Fiona
An unexpected meadow of the warm-water alga Penicillus capitatus was found thriving in sandy bottoms between 16 and 21 m depth in Mallorca, Balearic Islands. Plant densities and benthic coverage were very high when compared to most Mediterranean meadows of this species. As it is common in tropical meadows of this species, all the individuals were found in a Penicillus morphological state, whereas most Mediterranean individuals are always found in the filamentous (Espera) state. Due to the high biomass of the populations, the contribution to the primary productivity of the sandy bottoms it colonizes should be far from negligible. If the expansion of these species continues, the annual calcium carbonate production of the Balearic continental shelf will increase and previous estimated budgets will have to be reconsidered. Since no genetic analysis of the specimens have been performed so far, it is still early to know if the studied populations have been originated by native Mediterranean specimens or from a cryptic lineage of Western Atlantic or Macaronesian origin. Whatever the answer is, the current bloom of this population in an environment completely devoid of this species in the recent past, provides new evidence of the current tropicalization of the Mediterranean caused by global warming., Funding was provided by the “Invasion of the tropical alga Halimeda incrassata in the Balearic Islands: ecology and invasion dynamics (AAEE119/2017)”, funded by the Vicepresidencia y Consejería de Innovación, Investigación y Turismo del Govern de les Illes Balears, with support from the European Union and FEDER funds, and the project “Una nueva alga invasora en el Mediterráneo: invasibilidad, detección y erradicación del alga tropical Halimeda incrassata (INVHALI)”, funded by the Fundación Biodiversidad, del Ministerio para la Transición Ecológica y el Reto Demográfico to FT. IMEDEA is an accredited “Maria de Maeztu Excellence Unit” (Grant CEX2021-001198, funded by MICIU/AEI/10.13039/501100011033)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-00119)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Longitudinal association of shorter leukocyte telomere length with CSF biomarker dynamics across early Alzheimer's disease stages in at-risk individuals

  • Rodríguez-Fernández, Blanca
  • González-Escalante, Armand
  • Genius, Patricia
  • Evans, Tavia E.
  • Ortiz-Romero, Paula
  • Minguillón, Carolina
  • Kollmorgen, Gwendlyn
  • Ashton, Nicholas J
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Gispert, Juan Domingo
  • Navarro, Arcadi
  • Suárez-Calvet, Marc
  • Sala-Vila, Aleix
  • Crous-Bou, Marta
  • Vilor-Tejedor, Natàlia
  • ALFA study
Short telomere length (TL), a hallmark of biological ageing, has been associated with an increased risk of Alzheimer's disease (AD), but its pathophysiological role remains unclear. This study explored the relationship between blood leukocyte TL (LTL), cerebrospinal fluid (CSF) AD biomarkers changes, and brain structure across early stages of the AD continuum., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004; the Alzheimer's Association; and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. The project leading to these results has received funding from the Alzheimer's Association (Grant AARG-19–618265); Instituto de Salud Carlos III (PI19/00119); “la Caixa” Foundation under agreement LCF/PR/SC22/68000001; the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201); and the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (grant no. 2021 SGR 00913)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

  • Sanoja-Flores, L.
  • Flores-Montero, J.
  • Garces, J.J.
  • Paiva, B.
  • Puig, N.
  • Garcia-Mateo, A.
  • Garcia-Sanchez, O.
  • Corral-Mateos, A.
  • Burgos, L.
  • Blanco, E.
  • Hernandez-Martin, J.
  • Pontes, R.
  • Diez-Campelo, M.
  • Millacoy, P.
  • Rodriguez-Otero, P.
  • Prosper, F.
  • Merino, J.
  • Vidriales, M.B.
  • Garcia-Sanz, R.
  • Romero, A.
  • Palomera, L.
  • Rios-Tamayo, R.
  • Perez-Andres, M.
  • Blanco, J.F.
  • Gonzalez, M.
  • van Dongen, J.J.M.
  • Durie, B.
  • Mateos, M.V.
  • San-Miguel, J.
  • Orfao, A.
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p < 0.0001); in contrast, CTPC were present in a small fraction of solitary plasmacytoma patients (18%). Higher numbers of CTPC in PB were associated with higher levels of BM infiltration and more adverse prognostic features, together with shorter time to progression from MGUS to MM (p < 0.0001) and a shorter survival in MM patients with active disease requiring treatment (p <= 0.03). In summary, the presence of CTPC in PB as assessed by NGF at diagnosis, emerges as a hallmark of disseminated PCN, higher numbers of PB CTPC being strongly associated with a malignant disease behavior and a poorer outcome of both MGUS and MM.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Gut microbiota signature in treatment-naïve attention-deficit/hyperactivity disorder

  • Richarte Fernández, Vanesa
  • Sanchez Mora, Cristina P
  • Corrales De la Cruz, Montserrat
  • Fadeuilhe Grau, Christian
  • Vilar Ribo, Laura
  • Arribas Garcia, Lorena
  • Garcia Gea, Estela
  • Rosales Ortiz, Silvia Karina
  • Soler Artigas, Maria
  • Ribases Haro, Marta
  • Ramos-Quiroga, Josep Antoni
TDAH; Comunitat científica, TDAH; Comunidad científica, ADHD; Scientific community, Compelling evidence supports alterations in gut microbial diversity, bacterial composition, and/or relative abundance of several bacterial taxa in attention-deficit/hyperactivity disorder (ADHD). However, findings for ADHD are inconsistent among studies, and specific gut microbiome signatures for the disorder remain unknown. Given that previous studies have mainly focused on the pediatric form of the disorder and involved small sample sizes, we conducted the largest study to date to compare the gastrointestinal microbiome composition in 100 medication-naïve adults with ADHD and 100 sex-matched healthy controls. We found evidence that ADHD subjects have differences in the relative abundance of several microbial taxa. At the family level, our data support a lower relative abundance of Gracilibacteraceae and higher levels of Selenomonadaceae and Veillonellaceae in adults with ADHD. In addition, the ADHD group showed higher levels of Dialister and Megamonas and lower abundance of Anaerotaenia and Gracilibacter at the genus level. All four selected genera explained 15% of the variance of ADHD, and this microbial signature achieved an overall sensitivity of 74% and a specificity of 71% for distinguishing between ADHD patients and healthy controls. We also tested whether the selected genera correlate with age, body mass index (BMI), or scores of the ADHD rating scale but found no evidence of correlation between genera relative abundance and any of the selected traits. These results are in line with recent studies supporting gut microbiome alterations in neurodevelopment disorders, but further studies are needed to elucidate the role of the gut microbiota on the ADHD across the lifespan and its contribution to the persistence of the disorder from childhood to adulthood.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • hartman, catharina
  • Larsson, Henrik
  • Ribases, Marta
  • Mitjans, Marina
  • Soler Artigas, María
  • Demontis, Ditte
  • Ramos-Quiroga, Josep Antoni
Trastorno por déficit de atención e hiperactividad; Comorbilidad; Genética de trastornos cruzados, Trastorn per dèficit d'atenció i hiperactivitat; Comorbiditat; Genètica de trastorns creuats, Attention-deficit/hyperactivity disorder; Comorbidity; Cross-disorder genetics, Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable., This research has received funding from the EU’s Horizon 2020 research and innovation program under grant agreements no. 667302 (CoCA), 728018 (Eat2beNICE) and 2020604 (TIMESPAN) and from the ECNP Network ‘ADHD across the Lifespan' (https://www.ecnp.eu/researchinnovation/ECNP-networks/List-ECNP-Networks/). B Cormand has also been supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-1277760B-I100), the Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas (PNSD-2017I050), Fundació La Marató de TV3 (202218-31), Generalitat de Catalunya/AGAUR (2021-SGR-1093), ICREA Academia 2021 and the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 841899 (GRASAD) and 101028810 (ATTENTIVE). M Ribasés was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE), by the Instituto de Salud Carlos III (PI20/00041, CP09/00119 and CPII15/00023), by the Pla estratègic de recerca i innovació en salut (PERIS), Generalitat de Catalunya (METAL-Cat; SLT006/17/287), by the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461) and by Fundació La Marató de TV3 (202228-30, 202228-31). JA Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE). M Mitjans was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD), the MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR” (RYC2021-033573-I), Ministerio de Ciencia e Innovación (PID2022-139740OA-100) and the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2021-SGR-1093). M Soler Artigas was supported by the Instituto de Salud Carlos III (P19/01224, PI22/00464 and CP22/00128) and by the European Regional Development Fund. B Franke and A Reif were also supported by funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME). B Franke also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011). D Demontis is supported by the Novo Nordisk Foundation (NNF20OC0065561 and NNF21SA0072102), the Lundbeck Foundation (R344-2020-1060), the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 965381 (TIMESPAN). AD Børglum was supported by the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003). Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any of the other funding organisations mentioned here.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genome-wide analyses of aggressiveness in attention-deficit hyperactivity disorder

  • Brevik, Erlend J.
  • van Donkelaar, Marjolein M. J.
  • Weber, Heike|||0000-0002-9421-1292
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Jacob, Christian P.
  • Rivero, Olga|||0000-0002-2664-4053
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • García-Martinez, Iris|||0000-0001-6656-3322
  • Aebi, Marcel
  • van Hulzen, Kimm
  • Cormand, Bru|||0000-0001-5318-4382
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Lesch, Klaus-Peter|||0000-0001-8348-153X
  • Reif, Andreas|||0000-0002-0992-634X
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Franke, Barbara|||0000-0003-4375-6572
  • Posserud, Maj-Britt
  • Johansson, Stefan E.|||0000-0002-2298-7008
  • Lundervold, Astri J.|||0000-0002-6819-6164
  • Haavik, Jan|||0000-0001-7865-2808
  • Zayats, Tetyana
Aggressiveness is a behavioral trait that has the potential to be harmful to individuals and society. With an estimated heritability of about 40%, genetics is important in its development. We performed an exploratory genome-wide association (GWA) analysis of childhood aggressiveness in attention deficit hyperactivity disorder (ADHD) to gain insight into the underlying biological processes associated with this trait. Our primary sample consisted of 1,060 adult ADHD patients (aADHD). To further explore the genetic architecture of childhood aggressiveness, we performed enrichment analyses of suggestive genome-wide associations observed in aADHD among GWA signals of dimensions of oppositionality (defiant/vindictive and irritable dimensions) in childhood ADHD (cADHD). No single polymorphism reached genome-wide significance (P < 5.00E-08). The strongest signal in aADHD was observed at rs10826548, within a long noncoding RNA gene (beta = -1.66, standard error (SE) = 0.34, P = 1.07E-06), closely followed by rs35974940 in the neurotrimin gene (beta = 3.23, SE = 0.67, P = 1.26E-06). The top GWA SNPs observed in aADHD showed significant enrichment of signals from both the defiant/vindictive dimension (Fisher's P -value = 2.28E-06) and the irritable dimension in cADHD (Fisher's P -value = 0.0061). In sum, our results identify a number of biologically interesting markers possibly underlying childhood aggressiveness and provide targets for further genetic exploration of aggressiveness across psychiatric disorders.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preliminary evidence for association of genetic variants in pri-miR-34b/c and abnormal miR-34c expression with attention deficit and hyperactivity disorder

  • Garcia Martínez, I.
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Pagerols, Mireia|||0000-0003-0856-6247
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Cormand, Bru|||0000-0001-5318-4382
  • Casas, M.
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Ribasés, M..
Attention deficit and hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by impairment to sustain attention and inability to control impulses and activity level. The etiology of ADHD is complex, with an estimated heritability of 70-80%. Under the hypothesis that alterations in the processing or target binding of microRNAs (miRNAs) may result in functional alterations predisposing to ADHD, we explored whether common polymorphisms potentially affecting miRNA-mediated regulation are involved in this psychiatric disorder. We performed a comprehensive association study focused on 134 miRNAs in 754 ADHD subjects and 766 controls and found association between the miR-34b/c locus and ADHD. Subsequently, we provided preliminary evidence for overexpression of the miR-34c-3p mature form in peripheral blood mononuclear cells of ADHD subjects. Next, we tested the effect on gene expression of single-nucleotide polymorphisms within the ADHD-associated region and found that rs4938923 in the promoter of the pri-miR-34b/c tags cis expression quantitative trait loci for both miR-34b and miR-34c and has an impact on the expression levels of 681 transcripts in trans, including genes previously associated with ADHD. This gene set was enriched for miR-34b/c binding sites, functional categories related to the central nervous system, such as axon guidance or neuron differentiation, and serotonin biosynthesis and signaling canonical pathways. Our results provide preliminary evidence for the contribution to ADHD of a functional variant in the pri-miR-34b/c promoter, possibly through dysregulation of the expression of mature forms of miR-34b and miR-34c and some target genes. These data highlight the importance of abnormal miRNA function as a potential epigenetic mechanism contributing to ADHD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exome chip analyses in adult attention deficit hyperactivity disorder

  • Zayats, Tetyana
  • Jacobsen, K. K.
  • Kleppe, R.
  • Jacob, Christian P.
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • Ribasés, M..
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Mota, N. R.
  • Grevet, Eugenio Horacio
  • Klein, M.
  • Corominas Galbany, Jordi|||0000-0003-1736-1278
  • Bralten, Janita|||0000-0003-1440-8675
  • Galesloot, Tessel E.
  • Vasquez, A. A.
  • Herms, Stefan|||0000-0002-2786-8200
  • Forstner, A. J.
  • Larsson, Henrik
  • Breen, G.
  • Asherson, Philip|||0000-0003-2667-2254
  • Gross-Lesch, S.
  • Lesch, K. P.
  • Cichon, Sven|||0000-0002-9475-086X
  • Gabrielsen, M. B.
  • Holmen, O. L.
  • Bau, Claiton Henrique Dotto
  • Buitelaar, Jan|||0000-0001-8288-7757
  • Kiemeney, L.
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Cormand, Bru|||0000-0001-5318-4382
  • Franke, Barbara|||0000-0003-4375-6572
  • Reif, Andreas|||0000-0002-0992-634X
  • Haavik, Jan|||0000-0001-7865-2808
  • Johansson, S..
Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable childhood-onset neuropsychiatric condition, often persisting into adulthood. The genetic architecture of ADHD, particularly in adults, is largely unknown. We performed an exome-wide scan of adult ADHD using the Illumina Human Exome Bead Chip, which interrogates over 250 000 common and rare variants. Participants were recruited by the International Multicenter persistent ADHD CollaboraTion (IMpACT). Statistical analyses were divided into 3 steps: (1) gene-level analysis of rare variants (minor allele frequency (MAF)<1%); (2) single marker association tests of common variants (MAF⩾1%), with replication of the top signals; and (3) pathway analyses. In total, 9365 individuals (1846 cases and 7519 controls) were examined. Replication of the most associated common variants was attempted in 9847 individuals (2077 cases and 7770 controls) using fixed-effects inverse variance meta-analysis. With a Bonferroni-corrected significance level of 1.82E-06, our analyses of rare coding variants revealed four study-wide significant loci: 6q22.1 locus (P =4.46E-08), where NT5DC1 and COL10A1 reside; the SEC23IP locus (P =6.47E-07); the PSD locus (P =7.58E-08) and ZCCHC4 locus (P =1.79E-06). No genome-wide significant association was observed among the common variants. The strongest signal was noted at rs9325032 in PPP2R2B (odds ratio=0.81, P =1.61E-05). Taken together, our data add to the growing evidence of general signal transduction molecules (NT5DC1, PSD, SEC23IP and ZCCHC4) having an important role in the etiology of ADHD. Although the biological implications of these findings need to be further explored, they highlight the possible role of cellular communication as a potential core component in the development of both adult and childhood forms of ADHD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Subirana, Andrea
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Vanderstichele, Hugo
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Objective: We aimed to investigate the relationship between cerebrospinal fluid levels (CSF) of amyloid precursor protein (APP)-derived peptides related to the amyloidogenic pathway, cortical thickness, neuropsychological performance, and cortical gene expression profiles in frontotemporal lobar degeneration (FTLD)-related syndromes, Alzheimer's disease (AD), and healthy controls. Methods: We included 214 participants with CSF available recruited at two centers: 93 with FTLD-related syndromes, 57 patients with AD, and 64 healthy controls. CSF levels of amyloid β (Aβ)1-42, Aβ1-40, Aβ1-38, and soluble β fragment of APP (sAPPβ) were centrally analyzed. We compared CSF levels of APP-derived peptides between groups and, we studied the correlation between CSF biomarkers, cortical thickness, and domain-specific cognitive composites in each group. Then, we explored the relationship between cortical thickness, CSF levels of APP-derived peptides, and regional gene expression profile using a brain-wide regional gene expression data in combination with gene set enrichment analysis. Results: The CSF levels of Aβ1-40, Aβ1-38, and sAPPβ were lower in the FTLD-related syndromes group than in the AD and healthy controls group. CSF levels of all APP-derived peptides showed a positive correlation with cortical thickness and the executive cognitive composite in the FTLD-related syndromes group but not in the healthy control or AD groups. In the cortical regions where we observed a significant association between cortical thickness and CSF levels of APP-derived peptides, we found a reduced expression of genes related to synaptic function. Interpretation: APP-derived peptides in CSF may reflect FTLD-related neurodegeneration. This observation has important implications as Aβ1-42 levels are considered an indirect biomarker of cerebral amyloidosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan

  • Franke, Barbara|||0000-0003-4375-6572
  • Michelini, Giorgia
  • Asherson, Philip|||0000-0003-2667-2254
  • Banaschewski, Tobias
  • Bilbow, Andrea
  • Buitelaar, Jan|||0000-0001-8288-7757
  • Cormand, Bru|||0000-0001-5318-4382
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Ginsberg, Ylva
  • Haavik, Jan|||0000-0001-7865-2808
  • Kuntsi, Jonna|||0000-0002-0113-8162
  • Larsson, Henrik
  • Lesch, Klaus-Peter|||0000-0001-8348-153X
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Réthelyi, János M.
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Reif, Andreas|||0000-0002-0992-634X
Attention-deficit/hyperactivity disorder (ADHD) is highly heritable and the most common neurodevelopmental disorder in childhood. In recent decades, it has been appreciated that in a substantial number of cases the disorder does not remit in puberty, but persists into adulthood. Both in childhood and adulthood, ADHD is characterised by substantial comorbidity including substance use, depression, anxiety, and accidents. However, course and symptoms of the disorder and the comorbidities may fluctuate and change over time, and even age of onset in childhood has recently been questioned. Available evidence to date is poor and largely inconsistent with regard to the predictors of persistence versus remittance. Likewise, the development of comorbid disorders cannot be foreseen early on, hampering preventive measures. These facts call for a lifespan perspective on ADHD from childhood to old age. In this selective review, we summarise current knowledge of the long-term course of ADHD, with an emphasis on clinical symptom and cognitive trajectories, treatment effects over the lifespan, and the development of comorbidities. Also, we summarise current knowledge and important unresolved issues on biological factors underlying different ADHD trajectories. We conclude that a severe lack of knowledge on lifespan aspects in ADHD still exists for nearly every aspect reviewed. We encourage large-scale research efforts to overcome those knowledge gaps through appropriately granular longitudinal studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Pané, Adriana|||0000-0002-7810-1827
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Ibarzabal, Ainitze|||0000-0002-1220-6474
  • Casajoana, Anna
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • de Hollanda, Ana|||0000-0001-9114-8614
  • Vidal, Josep|||0000-0002-4564-4518
  • Ortega, Emilio|||0000-0002-2217-8905
  • Osorio, Ricardo|||0000-0002-2735-9609
  • Convit, Antonio
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
Midlife obesity is a risk factor for dementia. We investigated the impact of obesity on brain structure, metabolism, and cerebrospinal fluid (CSF) core Alzheimer's disease (AD) biomarkers in healthy elderly. We selected controls from ADNI2 with CSF AD biomarkers and/or fluorodeoxyglucose positron emission tomography (FDG-PET) and 3T-MRI. We measured cortical thickness, FDG uptake, and CSF amyloid beta (Aβ)1-42, p-tau, and t-tau levels. We performed regression analyses between these biomarkers and body mass index (BMI). We included 201 individuals (mean age 73.5 years, mean BMI 27.4 kg/m 2). Higher BMI was related to less cortical thickness and higher metabolism in brain areas typically not involved in AD (family-wise error [FWE] <0.05), but not to AD CSF biomarkers. It is notable that the impact of obesity on brain metabolism and structure was also found in amyloid negative individuals. In the cognitively unimpaired elderly, obesity has differential effects on brain metabolism and structure independent of an underlying AD pathophysiology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Shared genetic background between children and adults with attention deficit/hyperactivity disorder

  • Rovira, Paula|||0000-0003-2177-8412
  • Demontis, Ditte|||0000-0001-9124-2766
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Zayats, Tetyana
  • Klein, Marieke|||0000-0001-8784-5679
  • Mota, Nina Roth
  • Weber, Heike|||0000-0002-9421-1292
  • García-Martinez, Iris|||0000-0001-6656-3322
  • Pagerols, Mireia|||0000-0003-0856-6247
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Arribas, Lorena|||0000-0002-9683-9999
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Bosch, Rosa|||0000-0002-7596-183X
  • Martin, Gemma Español
  • Almos, Peter
  • Doyle, Alysa E.
  • Grevet, Eugenio Horacio
  • Grimm, Oliver|||0000-0002-0767-0301
  • Halmøy, Anne
  • Hoogman, Martine|||0000-0002-1261-7628
  • Hutz, Mara
  • Jacob, Christian P.
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • Knappskog, Per M.
  • Lundervold, Astri J.|||0000-0002-6819-6164
  • Rivero, Olga|||0000-0002-2664-4053
  • Rovaris, Diego Luiz|||0000-0002-8910-4927
  • Salatino-Oliveira, Angelica
  • da Silva, Bruna Santos
  • Svirin, Evgeniy|||0000-0003-3501-574X
  • Sprooten, Emma
  • Strekalova, Tatyana
  • Arias-Vásquez, Alejandro|||0000-0002-4786-0169
  • Sonuga-Barke, Edmund J. S.
  • Asherson, Philip|||0000-0003-2667-2254
  • Bau, Claiton Henrique Dotto
  • Buitelaar, Jan|||0000-0001-8288-7757
  • Cormand, Bru|||0000-0001-5318-4382
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Haavik, Jan|||0000-0001-7865-2808
  • Johansson, Stefan E.|||0000-0002-2298-7008
  • Kuntsi, Jonna|||0000-0002-0113-8162
  • Larsson, Henrik
  • Lesch, Klaus-Peter|||0000-0001-8348-153X
  • Reif, Andreas|||0000-0002-0992-634X
  • Rohde, Luis Augusto
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Børglum, Anders D.|||0000-0001-8627-7219
  • Franke, Barbara|||0000-0003-4375-6572
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Soler Artigas, María|||0000-0002-3213-1107
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by age-inappropriate symptoms of inattention, impulsivity, and hyperactivity that persist into adulthood in the majority of the diagnosed children. Despite several risk factors during childhood predicting the persistence of ADHD symptoms into adulthood, the genetic architecture underlying the trajectory of ADHD over time is still unclear. We set out to study the contribution of common genetic variants to the risk for ADHD across the lifespan by conducting meta-analyses of genome-wide association studies on persistent ADHD in adults and ADHD in childhood separately and jointly, and by comparing the genetic background between them in a total sample of 17,149 cases and 32,411 controls. Our results show nine new independent loci and support a shared contribution of common genetic variants to ADHD in children and adults. No subgroup heterogeneity was observed among children, while this group consists of future remitting and persistent individuals. We report similar patterns of genetic correlation of ADHD with other ADHD-related datasets and different traits and disorders among adults, children, and when combining both groups. These findings confirm that persistent ADHD in adults is a neurodevelopmental disorder and extend the existing hypothesis of a shared genetic architecture underlying ADHD and different traits to a lifespan perspective.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of ADHD risk genes in extended pedigrees by combining linkage analysis and whole-exome sequencing

  • Corominas Galbany, Jordi|||0000-0003-1736-1278
  • Klein, Marieke|||0000-0001-8784-5679
  • Zayats, Tetyana
  • Rivero, Olga|||0000-0002-2664-4053
  • Ziegler, Georg C.|||0000-0001-9411-3169
  • Pauper, Marc
  • Neveling, Kornelia
  • Poelmans, Geert
  • Jansch, Charline
  • Svirin, Evgeniy|||0000-0003-3501-574X
  • Geissler, Julia
  • Weber, Heike|||0000-0002-9421-1292
  • Reif, Andreas|||0000-0002-0992-634X
  • Arias-Vásquez, Alejandro|||0000-0002-4786-0169
  • Galesloot, Tessel E.
  • Kiemeney, Lambertus A. L. M.
  • Buitelaar, Jan|||0000-0001-8288-7757
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Cormand, Bru|||0000-0001-5318-4382
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Hveem, Kristian|||0000-0001-8157-9744
  • Gabrielsen, Maiken Elvestad
  • Hoffmann, Per|||0000-0002-6573-983X
  • Cichon, Sven|||0000-0002-9475-086X
  • Haavik, Jan|||0000-0001-7865-2808
  • Johansson, Stefan E.|||0000-0002-2298-7008
  • Jacob, Christian P.
  • Romanos, Marcel
  • Franke, Barbara|||0000-0003-4375-6572
  • Lesch, Klaus-Peter|||0000-0001-8348-153X
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder with a complex genetic background, hampering identification of underlying genetic risk factors. We hypothesized that combining linkage analysis and whole-exome sequencing (WES) in multi-generation pedigrees with multiple affected individuals can point toward novel ADHD genes. Three families with multiple ADHD-affected members (N = 70) and apparent dominant inheritance pattern were included in this study. Genotyping was performed in 37 family members, and WES was additionally carried out in 10 of those. Linkage analysis was performed using multi-point analysis in Superlink Online SNP 1.1. From prioritized linkage regions with a LOD score ≥ 2, a total of 24 genes harboring rare variants were selected. Those genes were taken forward and were jointly analyzed in gene-set analyses of exome-chip data using the MAGMA software in an independent sample of patients with persistent ADHD and healthy controls (N = 9365). The gene-set including all 24 genes together, and particularly the gene-set from one of the three families (12 genes), were significantly associated with persistent ADHD in this sample. Among the latter, gene-wide analysis for the AAED1 gene reached significance. A rare variant (rs151326868) within AAED1 segregated with ADHD in one of the families. The analytic strategy followed here is an effective approach for identifying novel ADHD risk genes. Additionally, this study suggests that both rare and more frequent variants in multiple genes act together in contributing to ADHD risk, even in individual multi-case families.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Relationship of Seminal Oxidation-Reduction Potential with Sperm DNA Integrity and pH in Idiopathic Infertile Patients

  • Garcia Segura, Sergio|||0000-0001-9594-2938
  • Ribas-Maynou, Jordi|||0000-0002-9101-2044
  • Lara Cerrillo, Sandra
  • García-Peiró, Agustín|||0000-0002-8492-3165
  • Belén Castel, Ana
  • Benet i Català, Jordi|||0000-0001-6185-2555
  • Oliver Bonet, Maria|||0000-0001-5635-6741
Seminal oxidative stress (OS) is one of the most promising factors to describe the causes of idiopathic male infertility. Redox balance is essential in several biological processes related to fertility, so alterations such as high reactive oxygen species (ROS) levels or low antioxidant agent levels can compromise it. MiOXSYS has been developed to evaluate the seminal static oxidation-reduction potential (sORP) and it has been proposed as an effective diagnostic biomarker. However, its relationship with parameters like sperm DNA fragmentation (SDF), chromatin compaction status or seminal pH requires further analysis, making it the object of this study. Semen and sORP analysis were performed for all samples. A terminal deoxynucleotidyl transferase dUTP nick end labeling assay (TUNEL) and Comet assay were used to assess SDF and chromomycin a3 (CMA3) test to assess sperm chromatin compaction. Regarding sORP measures, it was found that alkaline pH has an effect on sample reproducibility. To our knowledge, this unexpected effect has not been previously described. A statistical analysis showed that sORP correlated negatively with CMA3 positive cells and sperm motility, but not with SDF. As redox dysregulation, which occurs mainly at the testicular and epididymal level, causes chromatin compaction problems and leaves DNA exposed to damage, an excess of ROS could be counterbalanced further by a seminal supply of antioxidant molecules, explaining the negative correlation with CMA3 positive cells but no correlation with SDF. Our results show that the study of idiopathic infertility would benefit from a combined approach comprising OS analysis, SDF and chromatin compaction analysis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey

  • Hüls, Anke|||0000-0002-6005-417X
  • Costa, Alberto C. S.
  • Dierssen, Mara|||0000-0003-0853-6865
  • Baksh, Asaad|||0000-0001-6596-2145
  • Bargagna, Stefania
  • Baumer, Nicole
  • Brandão, Ana Claudia
  • Carfi, Angelo|||0000-0002-9837-7003
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Chicoine, Brian|||0000-0002-1520-3893
  • Ghosh, Sujay
  • Lakhanpaul, Monica
  • Manso, Coral
  • Mayer, Miguel-Angel
  • Ortega, Maria del Carmen
  • de Asua, Diego Real
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Russell, Lauren Ashley
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Sherman, Stephanie L.
  • Strydom, Andre
Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0.01), whereas altered consciousness/confusion were more frequent (p < 0.01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus non-DS patients: RR = 2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality. Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno Alcázar, Ana|||0000-0002-3392-5590
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Palomar, Gloria
  • Bosch, Rosa|||0000-0002-7596-183X
  • Salavert, Josep
  • Fortea, Lydia|||0000-0001-6778-2316
  • Monté-Rubio, Gemma C.|||0000-0002-3532-2224
  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Milham, Michael P.
  • Castellanos, Francisco X|||0000-0001-9192-9437
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Radua, Joaquim|||0000-0003-1240-5438
Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3 ; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene's relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Estellés, Teresa
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Muñoz, Lourdes
  • Ribosa-Nogué, Roser|||0000-0002-9233-4336
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lehmann, Stépánka
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of progression of several neurodegenerative diseases. Among them, CSF neurofilament light (NfL) protein has particular interest, as its levels reflect neuroaxonal degeneration, a common feature in various neurodegenerative diseases. In the present study, we analyzed NfL levels in the CSF of 535 participants of the SPIN (Sant Pau Initiative on Neurodegeneration) cohort including cognitively normal participants, patients with Alzheimer disease (AD), Down syndrome (DS), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). We evaluated the differences in CSF NfL accross groups and its association with other CSF biomarkers and with cognitive scales. All neurogenerative diseases showed increased levels of CSF NfL, with the highest levels in patients with ALS, FTD, CBS and PSP. Furthermore, we found an association of CSF NfL levels with cognitive impairment in patients within the AD and FTD spectrum and with AD pathology in DLB and DS patients. These results have implications for the use of NfL as a marker in neurodegenerative diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenome-wide association study of attention-deficit/hyperactivity disorder in adults

  • Rovira, Paula|||0000-0003-2177-8412
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Pagerols, Mireia|||0000-0003-0856-6247
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Arribas, Lorena|||0000-0002-9683-9999
  • Shireby, Gemma
  • Hannon, Eilis|||0000-0001-6840-072X
  • Mill, Jonathan|||0000-0003-1115-3224
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Soler Artigas, María|||0000-0002-3213-1107
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder that often persists into adulthood. There is growing evidence that epigenetic dysregulation participates in ADHD. Given that only a limited number of epigenome-wide association studies (EWASs) of ADHD have been conducted so far and they have mainly focused on pediatric and population-based samples, we performed an EWAS in a clinical sample of adults with ADHD. We report one CpG site and four regions differentially methylated between patients and controls, which are located in or near genes previously involved in autoimmune diseases, cancer or neuroticism. Our sensitivity analyses indicate that smoking status is not responsible for these results and that polygenic risk burden for ADHD does not greatly impact the signatures identified. Additionally, we show an overlap of our EWAS findings with genetic signatures previously described for ADHD and with epigenetic signatures for smoking behavior and maternal smoking. These findings support a role of DNA methylation in ADHD and emphasize the need for additional efforts in larger samples to clarify the role of epigenetic mechanisms on ADHD across the lifespan.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evaluation of biochemical and hematological parameters in adults with Down syndrome

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garzón, Diana
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Fortea, Juan|||0000-0002-1340-638X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
Down syndrome (DS) is the most common worldwide cause of intellectual disability of genetic origin and the most common chromosomal disorder affecting live-born infants. In addition to intellectual disability, individuals with DS have other comorbidities and complex medical conditions. The increase in the life expectancy of patients with DS requires expanding the knowledge about their clinical characteristics and related laboratory parameters. Several studies exploring laboratory tests in DS patients exist, but their focus is limited to specific areas of metabolism. Therefore, our main goal was to describe the biochemical and hematological findings in a DS cohort and to compare the values to those of a control population. A total of 248 DS individuals and 84 control subjects were enrolled. DS individuals had a higher frequency of several clinical conditions compared to control individuals and presented with significant differences with respect to the controls in both biochemical and hematological parameters. We found age- and sex-related differences in several of the parameters. A good understanding of the differences in our cohort might be of aid in the clinical follow-up of adults with DS, especially considering that the lifespan of DS individuals may reach 60 years of age in developed countries.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder

  • Pagerols, Mireia|||0000-0003-0856-6247
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Rovira, Paula|||0000-0003-2177-8412
  • Soler Artigas, María|||0000-0002-3213-1107
  • García-Martinez, Iris|||0000-0001-6656-3322
  • Calvo-Sánchez, Eva|||0000-0001-8211-6047
  • Corrales, Montserrat|||0000-0002-7428-1402
  • da Silva, Bruna Santos
  • Mota, Nina Roth
  • Moraes Victor, Marcelo
  • Rohde, Luis Augusto
  • Grevet, Eugenio Horacio
  • Bau, Claiton Henrique Dotto
  • Cormand, Bru|||0000-0001-5318-4382
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Methylphenidate (MPH) is the most frequently used pharmacological treatment in children with attention-deficit/hyperactivity disorder (ADHD). However, a considerable interindividual variability exists in clinical outcome. Thus, we performed a genome-wide association study of MPH efficacy in 173 ADHD paediatric patients. Although no variant reached genome-wide significance, the set of genes containing single-nucleotide polymorphisms (SNPs) nominally associated with MPH response (P < 0.05) was significantly enriched for candidates previously studied in ADHD or treatment outcome. We prioritised the nominally significant SNPs by functional annotation and expression quantitative trait loci (eQTL) analysis in human brain, and we identified 33 SNPs tagging cis -eQTL in 32 different loci (referred to as eSNPs and eGenes, respectively). Pathway enrichment analyses revealed an over-representation of genes involved in nervous system development and function among the eGenes. Categories related to neurological diseases, psychological disorders and behaviour were also significantly enriched. We subsequently meta-analysed the association with clinical outcome for the 33 eSNPs across the discovery sample and an independent cohort of 189 ADHD adult patients (target sample) and we detected 15 suggestive signals. Following this comprehensive strategy, our results provide a better understanding of the molecular mechanisms implicated in MPH treatment effects and suggest promising candidates that may encourage future studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Response of the human myocardium to ischemic injury and preconditioning, The role of cardiac and comorbid conditions, medical treatment, and basal redox status

  • Casós, Kelly
  • Ferrer-Curriu, Gemma|||0000-0002-2651-649X
  • Soler-Ferrer, Paula
  • Pérez, María-Llanos
  • Permanyer, Eduard
  • Blasco-Lucas, Arnau|||0000-0002-2796-7428
  • Gracia Baena, Juan Manuel|||0000-0001-5277-3847
  • Castro, Miguel A.
  • Sureda-Barbosa, Carlos
  • Barquinero Mañez, Jordi|||0000-0002-1677-9851
  • Galiñanes, Manuel|||0000-0002-0888-976X
The diseased human myocardium is highly susceptible to ischemia/reoxygenation (I/R)-induced injury but its response to protective interventions such as ischemic preconditioning (IPreC) is unclear. Cardiac and other pre-existing clinical conditions as well as previous or ongoing medical treatment may influence the myocardial response to I/R injury and protection. This study investigated the effect of both on myocardial susceptibility to I/R-induced injury and the protective effects of IPreC. Atrial myocardium from cardiac surgery patients (n = 300) was assigned to one of three groups: aerobic control, I/R alone, and IPreC. Lactate dehydrogenase leakage, as a marker of cell injury, and cell viability were measured. The basal redox status was determined in samples from 90 patients. The response to I/R varied widely. Myocardium from patients with aortic valve disease was the most susceptible to injury whereas myocardium from dyslipidemia patients was the least susceptible. Tissue from females was better protected than tissue from males. Myocardium from patients with mitral valve disease was the least responsive to IPreC. The basal redox status was altered in the myocardium from patients with mitral and aortic valve disease. The response of the myocardium to I/R and IPreC is highly variable and influenced by the underlying cardiac pathology, dyslipidemia, sex, and the basal redox status. These results should be taken into account in the design of future clinical studies on the prevention of I/R injury and protection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gene-wide Association Study Reveals RNF122 Ubiquitin Ligase as a Novel Susceptibility Gene for Attention Deficit Hyperactivity Disorder

  • García-Martinez, Iris|||0000-0001-6656-3322
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Soler Artigas, María|||0000-0002-3213-1107
  • Rovira, Paula|||0000-0003-2177-8412
  • Pagerols, Mireia|||0000-0003-0856-6247
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Calvo-Sánchez, Eva|||0000-0001-8211-6047
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Sunyer, Jordi
  • Cormand, Bru|||0000-0001-5318-4382
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention Deficit Hyperactivity Disorder (ADHD) is a common childhood-onset neurodevelopmental condition characterized by pervasive impairment of attention, hyperactivity, and/or impulsivity that can persist into adulthood. The aetiology of ADHD is complex and multifactorial and, despite the wealth of evidence for its high heritability, genetic studies have provided modest evidence for the involvement of specific genes and have failed to identify consistent and replicable results. Due to the lack of robust findings, we performed gene-wide and pathway enrichment analyses using pre-existing GWAS data from 607 persistent ADHD subjects and 584 controls, produced by our group. Subsequently, expression profiles of genes surpassing a follow-up threshold of P-value < 1e-03 in the gene-wide analyses were tested in peripheral blood mononucleated cells (PBMCs) of 45 medication-naive adults with ADHD and 39 healthy unrelated controls. We found preliminary evidence for genetic association between RNF122 and ADHD and for its overexpression in adults with ADHD. RNF122 encodes for an E3 ubiquitin ligase involved in the proteasome-mediated processing, trafficking, and degradation of proteins that acts as an essential mediator of the substrate specificity of ubiquitin ligation. Thus, our findings support previous data that place the ubiquitin-proteasome system as a promising candidate for its involvement in the aetiology of ADHD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of the PLCB1 gene with drug dependence

  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Roncero, Carlos|||0000-0003-1421-7385
  • Pineda-Cirera, Laura|||0000-0002-4701-7657
  • Palma-Álvarez, Raúl Felipe|||0000-0002-6428-9865
  • Ros-Cucurull, Elena
  • Grau-López, Lara|||0000-0003-1297-1819
  • Esojo, Abderaman|||0000-0003-4669-1639
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Arenas Solà, Concepción|||0000-0002-6489-4934
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Fernàndez-Castillo, Noèlia|||0000-0001-9948-0312
  • Cormand, Bru|||0000-0001-5318-4382
Genetic factors involved in the susceptibility to drug addiction still remain largely unknown. MiRNAs seem to play key roles in the drug-induced plasticity of the brain that likely drives the emergence of addiction. In this work we explored the role of miRNAs in drug addiction. With this aim, we selected 62 SNPs located in the 3'UTR of target genes that are predicted to alter the binding of miRNA molecules and performed a case-control association study in a Spanish sample of 735 cases (mainly cocaine-dependent subjects with multiple drug dependencies) and 739 controls. We found an association between rs1047383 in the PLCB1 gene and drug dependence that was replicated in an independent sample (663 cases and 667 controls). Then we selected 9 miRNAs predicted to bind the rs1047383 region, but none of them showed any effect on PLCB1 expression. We also assessed two miRNAs binding a region that contains a SNP in linkage disequilibrium with rs1047383, but although one of them, hsa-miR-582, was found to downregulate PLCB1, no differences were observed between alleles. Finally, we explored the possibility that PLCB1 expression is altered by cocaine and we observed a significant upregulation of the gene in the nucleus accumbens of cocaine abusers and in human dopaminergic-like neurons after cocaine treatment. Our results, together with previous studies, suggest that PLCB1 participates in the susceptibility to drug dependence.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Highly Polymorphic Copy Number Variant in the NSF Gene is Associated with Cocaine Dependence

  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Roncero, Carlos|||0000-0003-1421-7385
  • Grau-López, Lara|||0000-0003-1297-1819
  • Rodríguez-Cintas, Laia|||0000-0003-2703-6225
  • Barral, Carmen|||0000-0001-9963-6153
  • Abad, Alfonso Carlos|||0000-0001-5706-7693
  • Erikson, Galina
  • Wineinger, Nathan E.
  • Torrico, Bàrbara
  • Arenas Solà, Concepción|||0000-0002-6489-4934
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Cormand, Bru|||0000-0001-5318-4382
  • Fernàndez-Castillo, Noèlia|||0000-0001-9948-0312
Cocaine dependence is a complex psychiatric disorder involving both genetic and environmental factors. Several neurotransmitter systems mediate cocaine's effects, dependence and relapse, being the components of the neurotransmitter release machinery good candidates for the disorder. Previously, we identified a risk haplotype for cocaine dependence in the NSF gene, encoding the protein N-Ethylmaleimide-Sensitive Factor essential for synaptic vesicle turnover. Here we examined the possible contribution to cocaine dependence of a large copy number variant (CNV) that encompasses part of the NSF gene. We performed a case-control association study in a discovery sample (359 cases and 356 controls) and identified an association between cocaine dependence and the CNV (P = 0.013), that was confirmed in the replication sample (508 cases and 569 controls, P = 7.1e-03) and in a pooled analysis (P = 1.8e-04), with an over-representation of low number of copies in cases. Subsequently, we studied the functional impact of the CNV on gene expression and found that the levels of two NSF transcripts were significantly increased in peripheral blood mononuclear cells (PBMC) along with the number of copies of the CNV. These results, together with a previous study from our group, support the role of NSF in the susceptibility to cocaine dependence.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Serum Levels of TWEAK and Scavenger Receptor CD163 in Type 1 Diabetes Mellitus, Relationship with Cardiovascular Risk Factors. A Case-Control Study

  • Llauradó, Gemma|||0000-0002-3237-6366
  • González Clemente, José Miguel|||0000-0002-7409-8720
  • Maymó-Masip, Elsa
  • Subías, David
  • Vendrell, Joan|||0000-0002-6994-6115
  • Chacón, Matilde R.
To test the usefulness of serum concentrations of tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and soluble scavenger receptor CD163 (sCD163) as markers of subtle inflammation in patients with type 1 diabetes mellitus (T1DM) without clinical cardiovascular (CV) disease and to evaluate their relationship with arterial stiffness (AS). Sixty-eight patients with T1DM and 68 age and sex-matched, healthy subjects were evaluated. Anthropometrical variables and CV risk factors were recorded. Serum concentrations of sTWEAK and sCD163 were measured. AS was assessed by aortic pulse wave velocity (aPWV). All statistical analyses were stratified by gender. T1DM patients showed lower serum concentrations of sTWEAK (Men: 1636.5 (1146.3-3754.8) pg/mL vs. 765.9 (650.4-1097.1) pg/mL; p<0.001. Women: 1401.0 (788.0-2422.2) pg/mL vs. 830.1 (562.6-1175.9) pg/mL; p = 0.011) compared with their respective controls. Additionally, T1DM men had higher serum concentrations of sCD163 (285.0 (247.7-357.1) ng/mL vs. 224.8 (193.3-296.5) ng/mL; p = 0.012) compared with their respective controls. sTWEAK correlated negatively with aPWV in men (r = -0.443; p<0.001). However, this association disappeared after adjusting for potential confounders. In men, the best multiple linear regression model showed that the independent predictors of sTWEAK were T1DM and WHR (R 2 = 0.640; p<0.001). In women, T1DM and SBP were the independent predictors for sTWEAK (R 2 = 0.231; p = 0.001). sTWEAK is decreased in T1DM patients compared with age and sex-matched healthy subjects after adjusting for classic CV risk factors, although sTWEAK levels may be partially influenced by some of them. Additionally, T1DM men have higher serum concentrations of sCD163. These results point out an association between the inflammatory system and CV risk in T1DM.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders

  • Ramírez, Sara
  • Haddad-Tóvolli, Roberta
  • Radosevic, Marija
  • Toledo, Miriam
  • Pané, Adriana|||0000-0002-7810-1827
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Ribas Ripoll, Vicent|||0000-0002-7266-6106
  • Milà-Guasch, Maria
  • Pozo, Macarena
  • Obri, Arnaud
  • Eyre Sánchez, Elena
  • Gómez-Valadés, Alicia G.
  • Chivite, Iñigo
  • Van Eeckhout, Tomas
  • Zalachoras, Ioannis
  • Altirriba, Jordi
  • Bauder, Corinna
  • Imbernón, Mónica
  • Garrabou, Glòria|||0000-0001-8973-9933
  • Garcia-Ruiz, Carmen
  • Nogueiras, Rubén|||0000-0002-9976-9930
  • Soto, David
  • Gasull, Xavier|||0000-0002-6154-8323
  • Sandi, Carmen|||0000-0001-7713-8321
  • Brüning, Jens C.
  • Fortea, Juan|||0000-0002-1340-638X
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Fernández-Checa, José C.
  • Claret, Marc
Obesity and type 2 diabetes are associated with cognitive dysfunction. Because the hypothalamus is implicated in energy balance control and memory disorders, we hypothesized that specific neurons in this brain region are at the interface of metabolism and cognition. Acute obesogenic diet administration in mice impaired recognition memory due to defective production of the neurosteroid precursor pregnenolone in the hypothalamus. Genetic interference with pregnenolone synthesis by Star deletion in hypothalamic POMC, but not AgRP neurons, deteriorated recognition memory independently of metabolic disturbances. Our data suggest that pregnenolone's effects on cognitive function were mediated via an autocrine mechanism on POMC neurons, influencing hippocampal long-term potentiation. The relevance of central pregnenolone on cognition was also confirmed in metabolically unhealthy patients with obesity. Our data reveal an unsuspected role for POMC neuron-derived neurosteroids in cognition. These results provide the basis for a framework to investigate new facets of POMC neuron biology with implications for cognitive disorders. Ramírez et al. show that reduced hypothalamic pregnenolone levels, in the context of metabolic diseases, are associated with cognitive deterioration. POMC neuron-derived pregnenolone is a key mediator of cognition, but not metabolism, acting via hippocampal mechanisms. These results identify an unsuspected role for POMC neuron-derived pregnenolone in memory performance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

AMYQ, An index to standardize quantitative amyloid load across PET tracers

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Aranha, Mateus|||0000-0001-9594-292X
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carrió, Ignasi|||0000-0003-1135-5352
  • Camacho, Valle|||0000-0003-0748-0847
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Positron emission tomography (PET) amyloid quantification methods require magnetic resonance imaging (MRI) for spatial registration and a priori reference region to scale the images. Furthermore, different tracers have distinct thresholds for positivity. We propose the AMYQ index, a new measure of amyloid burden, to overcome these limitations. We selected 18F-amyloid scans from ADNI and Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) with the corresponding T1-MRI. A subset also had neuropathological data. PET images were normalized, and the AMYQ was calculated based on an adaptive template. We compared AMYQ with the Centiloid scale on clinical and neuropathological diagnostic performance. AMYQ was related with amyloid neuropathological burden and had excellent diagnostic performance to discriminate controls from patients with Alzheimer's disease (AD) (area under the curve [AUC] = 0.86). AMYQ had a high agreement with the Centiloid scale (intraclass correlation coefficient [ICC] = 0.88) and AUC between 0.94 and 0.99 to discriminate PET positivity when using different Centiloid cutoffs. AMYQ is a new MRI-independent index for standardizing and quantifying amyloid load across tracers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus

  • García-Crespo, Carlos|||0000-0001-6561-5389
  • Gallego, Isabel
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • de Ávila, Ana Isabel
  • Martínez-González, Brenda|||0000-0002-4482-5181
  • Vázquez-Sirvent, Lucía
  • Lobo-Vega, Rebeca|||0000-0002-4882-6763
  • Moreno del Olmo, Elena|||0000-0002-2301-4558
  • Gómez, Jordi
  • Briones Llorente, Carlos|||0000-0003-2213-8353
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Domingo, Esteban
  • Perales Viejo, Celia|||0000-0003-1618-1937
Replication of RNA viruses is characterized by exploration of sequence space which facilitates their adaptation to changing environments. It is generally accepted that such exploration takes place mainly in response to positive selection, and that further diversification is boosted by modifications of virus population size, particularly bottleneck events. Our recent results with hepatitis C virus (HCV) have shown that the expansion in sequence space of a viral clone continues despite prolonged replication in a stable cell culture environment. Diagnosis of the expansion was based on the quantification of diversity indices, the occurrence of intra-population mutational waves (variations in mutant frequencies), and greater individual residue variations in mutant spectra than those anticipated from sequence alignments in data banks. In the present report, we review our previous results, and show additionally that mutational waves in amplicons from the NS5A-NS5B-coding region are equally prominent during HCV passage in the absence or presence of the mutagenic nucleotide analogues favipiravir or ribavirin. In addition, by extending our previous analysis to amplicons of the NS3- and NS5A-coding region, we provide further evidence of the incongruence between amino acid conservation scores in mutant spectra from infected patients and in the Los Alamos National Laboratory HCV data banks. We hypothesize that these observations have as a common origin a permanent state of HCV population disequilibrium even upon extensive viral replication in the absence of external selective constraints or changes in population size. Such a persistent disequilibrium-revealed by the changing composition of the mutant spectrum-may facilitate finding alternative mutational pathways for HCV antiviral resistance. The possible significance of our model for other genetically variable viruses is discussed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gut microbiota signature in treatment-naïve attention-deficit/hyperactivity disorder

  • Richarte, Vanesa|||0000-0001-7327-318X
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Arribas, Lorena|||0000-0002-9683-9999
  • García-Estela, Aitana|||0000-0001-8529-544X
  • Rosales, Silvia Karina|||0000-0003-0834-7423
  • Arias-Vásquez, Alejandro|||0000-0002-4786-0169
  • Soler Artigas, María|||0000-0002-3213-1107
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
Compelling evidence supports alterations in gut microbial diversity, bacterial composition, and/or relative abundance of several bacterial taxa in attention-deficit/hyperactivity disorder (ADHD). However, findings for ADHD are inconsistent among studies, and specific gut microbiome signatures for the disorder remain unknown. Given that previous studies have mainly focused on the pediatric form of the disorder and involved small sample sizes, we conducted the largest study to date to compare the gastrointestinal microbiome composition in 100 medication-naïve adults with ADHD and 100 sex-matched healthy controls. We found evidence that ADHD subjects have differences in the relative abundance of several microbial taxa. At the family level, our data support a lower relative abundance of Gracilibacteraceae and higher levels of Selenomonadaceae and Veillonellaceae in adults with ADHD. In addition, the ADHD group showed higher levels of Dialister and Megamonas and lower abundance of Anaerotaenia and Gracilibacter at the genus level. All four selected genera explained 15% of the variance of ADHD, and this microbial signature achieved an overall sensitivity of 74% and a specificity of 71% for distinguishing between ADHD patients and healthy controls. We also tested whether the selected genera correlate with age, body mass index (BMI), or scores of the ADHD rating scale but found no evidence of correlation between genera relative abundance and any of the selected traits. These results are in line with recent studies supporting gut microbiome alterations in neurodevelopment disorders, but further studies are needed to elucidate the role of the gut microbiota on the ADHD across the lifespan and its contribution to the persistence of the disorder from childhood to adulthood.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome

  • Lleó, Alberto|||0000-0002-2568-5478
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Montal, Victor|||0000-0002-5714-9282
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, Susana|||0000-0002-9777-1156
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Garzón, Diana
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Camacho, Valle|||0000-0003-0748-0847
  • Medrano-Martorell, Santiago|||0000-0002-6586-7284
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Blennow, Kaj|||0000-0002-1890-4193
  • Fortea, Juan|||0000-0002-1340-638X
  • Zetterberg, Henrik|||0000-0003-3930-4354
Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS. Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology. Here, the authors investigated whether plasma ptau181 could be a potential biomarker of AD in individuals with Down syndrome (DS) and find plasma p-tau181 can detect AD in DS adults.
Dipòsit Digital de Documents de la UAB
Research data Set de datos (Dataset)

Metadata and relative abundance of seminal microbiota from idiopathic infertile patients and donors

  • Garcia Segura, Sergio|||0000-0001-9594-2938
  • Oliver Bonet, Maria|||0000-0001-5635-6741
  • Benet i Català, Jordi|||0000-0001-6185-2555
Data set obtained as a result of the sequencing by Illumina platform and subsequent taxonomic classification of the 16S rRNA gene of seminal microbiota from idiopathic infertile men and donors. The results are shown in terms of relative abundance of each bactera identified for each individual and are grouped into spreadsheets by taxonomic level (phylum, family, and genera). Each individual also presents metadata regarding information about their lifestyle, intake habits, clinical history, and analysis of their sperm quality parameters (seminogram, oxidative stress and sperm DNA integrity).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease

  • Giménez, Sandra|||0000-0001-8031-2319
  • Farre, Ariadna
  • Morente, Fátima
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Gutiérrez, Marta
  • Clos, Susana|||0000-0001-5350-821X
  • Fernández-Arcos, Ana
  • Blanco, Marta
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Asensio, Amparo
  • Benejam, Bessy|||0000-0002-6789-8615
  • Batista, Mar
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fortuna Gutiérrez, Ana Mª|||0000-0002-3619-1609
  • Fortea, Juan|||0000-0002-1340-638X
  • Mayos, Merce|||0000-0003-3972-3671
.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

TMT-Based Proteomic Analysis of Human Spermatozoa from Unexplained Recurrent Miscarriage Patients before and after Oral Antioxidant Treatment

  • Fernandez Encinas, Alba|||0000-0003-2701-4739
  • Ribas-Maynou, Jordi|||0000-0002-9101-2044
  • García-Peiró, Agustín|||0000-0002-8492-3165
  • Garcia Segura, Sergio|||0000-0001-9594-2938
  • Martinez-Pasarell, Olga|||0000-0002-9760-2854
  • Navarro i Ferreté, Joaquima|||0000-0002-9245-2260
  • Oliver Bonet, Maria|||0000-0001-5635-6741
  • Benet i Català, Jordi|||0000-0001-6185-2555
Recently, sperm quality and the presence of double-stranded breaks (DSB) has been pointed out as a possible cause of recurrent miscarriage, and the use of antioxidants has expanded as a treatment for male infertility. The aim of the present study was to analyze the proteomic effects of antioxidants on sperm from RM patients with high incidence of DSB. Proteomic analysis was performed using a tandem mass tag labeling technique, and subsequently compared with the PANTHER database for DEPs, and the STRING database for protein-protein interactions (PPI). Differentially expressed proteins (DEPs) both before and after antioxidant oral treatment were identified. PPI involving DEPs clustered into networks related to cell metabolism, cytoskeleton, and DNA damage. Results show that the sperm proteomic profiles before and after antioxidant treatment do not significantly differ from each other. However, some DEPs found after the antioxidant treatment shifted towards a DEPs profile typical of fertile donors. This indirect measurement suggests an improvement caused by antioxidants on the expression of several proteins. Among them were proteins involved in sperm DNA remodeling (LMO7, MMP28, BNC2, H2B, and PRDM2). The results presented here represent the first approach in the analysis and repair of the proteomic change caused by antioxidants in recurrent miscarriage patients, elucidating biomarkers that may be useful for the diagnosis and further sperm selection in this type of patient. Further studies should be conducted to validate the usefulness of these biomarkers in larger study groups.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Polygenic association between attention-deficit/hyperactivity disorder liability and cognitive impairments

  • Vainieri, Isabella|||0000-0002-3555-2345
  • Martin, Joanna
  • Rommel, Anna-Sophie
  • Asherson, Philip|||0000-0003-2667-2254
  • Banaschewski, Tobias
  • Buitelaar, Jan|||0000-0001-8288-7757
  • Cormand, Bru|||0000-0001-5318-4382
  • Crosbie, Jennifer
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Franke, Barbara|||0000-0003-4375-6572
  • Loo, Sandra K.
  • Miranda, Ana
  • Manor, Iris
  • Oades, Robert D.
  • Purves, Kirstin L.
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Roeyers, Herbert
  • Rothenberger, Aribert
  • Schachar, Russell
  • Sergeant, Joseph
  • Steinhausen, Hans-Christoph
  • Vuijk, Pieter J.
  • Doyle, Alysa E.
  • Kuntsi, Jonna|||0000-0002-0113-8162
A recent genome-wide association study (GWAS) identified 12 independent loci significantly associated with attention-deficit/hyperactivity disorder (ADHD). Polygenic risk scores (PRS), derived from the GWAS, can be used to assess genetic overlap between ADHD and other traits. Using ADHD samples from several international sites, we derived PRS for ADHD from the recent GWAS to test whether genetic variants that contribute to ADHD also influence two cognitive functions that show strong association with ADHD: attention regulation and response inhibition, captured by reaction time variability (RTV) and commission errors (CE). The discovery GWAS included 19 099 ADHD cases and 34 194 control participants. The combined target sample included 845 people with ADHD (age: 8-40 years). RTV and CE were available from reaction time and response inhibition tasks. ADHD PRS were calculated from the GWAS using a leave-one-study-out approach. Regression analyses were run to investigate whether ADHD PRS were associated with CE and RTV. Results across sites were combined via random effect meta-analyses. When combining the studies in meta-analyses, results were significant for RTV (R 2 = 0.011, β = 0.088, p = 0.02) but not for CE (R 2 = 0.011, β = 0.013, p = 0.732). No significant association was found between ADHD PRS and RTV or CE in any sample individually (p.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of Apolipoprotein e ϵ4 Allele with Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults with down Syndrome

  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernandez, S.
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Muñoz, Laia|||0000-0003-0578-3094
  • Padilla, Concepción|||0000-0003-4102-6787
  • Aranha, Mateus|||0000-0001-9594-292X
  • Estellés, Teresa
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Belbin, Olivia|||0000-0002-6109-6371
  • Camacho, Valle|||0000-0003-0748-0847
  • Wilson, Liam Reese
  • Annus, Tiina
  • Osorio, R.S.
  • Videla, S.
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Holland, Anthony|||0000-0003-4107-130X
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Zaman, Shahid
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Importance: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ϵ4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce. Objective: To investigate the association of the APOE ϵ4 allele with clinical and multimodal biomarkers of AD in adults with DS. Design, Setting, and Participants: This dual-center cohort study recruited adults with DS in Barcelona, Spain, and in Cambridge, UK, between June 1, 2009, and February 28, 2020. Included individuals had been genotyped for APOE and had at least 1 clinical or AD biomarker measurement; 2 individuals were excluded because of the absence of trisomy 21. Participants were either APOE ϵ4 allele carriers or noncarriers. Main Outcomes and Measures: Participants underwent a neurological and neuropsychological assessment. A subset of participants had biomarker measurements: Aβ1-42, Aβ1-40, phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) in cerebrospinal fluid (CSF), pTau181, and NfL in plasma; amyloid positron emission tomography (PET); fluorine 18-labeled-fluorodeoxyglucose PET; and/or magnetic resonance imaging. Age at symptom onset was compared between APOE ϵ4 allele carriers and noncarriers, and within-group local regression models were used to compare the association of biomarkers with age. Voxelwise analyses were performed to assess topographical differences in gray matter metabolism and volume. Results: Of the 464 adults with DS included in the study, 97 (20.9%) were APOE ϵ4 allele carriers and 367 (79.1%) were noncarriers. No differences between the 2 groups were found by age (median [interquartile range], 45.9 [36.4-50.2] years vs 43.7 [34.9-50.2] years; P =.56) or sex (51 male carriers [52.6%] vs 199 male noncarriers [54.2%]). APOE ϵ4 allele carriers compared with noncarriers presented with AD symptoms at a younger age (mean [SD] age, 50.7 [4.4] years vs 52.7 [5.8] years; P =.02) and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by nonoverlapping CIs. Specifically, carriers showed lower levels of the CSF Aβ1-42 to Aβ1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE ϵ4 allele carriers. Conclusions and Relevance: In this study, the APOE ϵ4 allele was associated with earlier clinical and biomarker changes of AD in DS. These results provide insights into the mechanisms by which APOE increases the risk of AD, emphasizing the importance of APOE genotype for future clinical trials in DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The clinical and neuropathological features of sporadic (Late-onset) and genetic forms of alzheimer's disease

  • Rujeedawa, Tanzil|||0000-0002-7089-1684
  • Carrillo Félez, Eva
  • Clare, Isabel C.H.|||0000-0002-5385-008X
  • Fortea, Juan|||0000-0002-1340-638X
  • Strydom, Andre
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Coppus, Antonia
  • Levin, Johannes|||0000-0001-5092-4306
  • Zaman, Shahid
The purpose of this review is to compare and highlight the clinical and pathological aspects of genetic versus acquired Alzheimer's disease: Down syndrome-associated Alzheimer's disease in (DSAD) and Autosomal Dominant Alzheimer's disease (ADAD) are compared with the late-onset form of the disease (LOAD). DSAD and ADAD present in a younger population and are more likely to manifest with non-amnestic (such as dysexecutive function features) in the prodromal phase or neurological features (such as seizures and paralysis) especially in ADAD. The very large variety of mutations associated with ADAD explains the wider range of phenotypes. In the LOAD, age-associated comorbidities explain many of the phenotypic differences.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Seminal Microbiota of Idiopathic Infertile Patients and Its Relationship With Sperm DNA Integrity

  • Garcia Segura, Sergio|||0000-0001-9594-2938
  • Rey Azpiri, Javier del|||0000-0001-7887-7871
  • Closa, Laia|||0000-0001-8007-5077
  • García-Martinez, Iris|||0000-0001-6656-3322
  • Hobeich, Carlos
  • Castel, Ana Belén
  • Vidal, Francisco|||0000-0001-8089-4945
  • Benet i Català, Jordi|||0000-0001-6185-2555
  • Ribas-Maynou, Jordi|||0000-0002-9101-2044
  • Oliver Bonet, Maria|||0000-0001-5635-6741
The development of new biomarkers for human male infertility is crucial to improve the diagnosis and the prognosis of this disease. Recently, seminal microbiota was shown to be related to sperm quality parameters, suggesting an effect in human fertility and postulating it as a biomarker candidate. However, its relationship to sperm DNA integrity has not been studied yet. The aim of the present study is to characterize the seminal microbiota of a western Mediterranean population and to evaluate its relationship to sperm chromatin integrity parameters, and oxidative stress. For that purpose, 14 samples from sperm donors and 42 samples from infertile idiopathic patients were obtained and were analyzed to assess the composition of the microbiota through full-length 16S rRNA gene sequencing (Illumina MiSeq platform). Microbial diversity and relative abundances were compared to classic sperm quality parameters (macroscopic semen parameters, motility, morphology and concentration), chromatin integrity (global DNA damage, double-stranded DNA breaks and DNA protamination status) and oxidative stress levels (oxidation-reduction potential). The seminal microbiota observed of these samples belonged to the phyla Firmicutes, Proteobacteria, Actinobacteria and Bacteroidetes. The most abundant genera were Finegoldia, Peptoniphilus, Anaerococcus, Campylobacter, Streptococcus, Staphylococcus, Moraxella, Prevotella, Ezakiella, Corynebacterium and Lactobacillus. To our knowledge, this is the first detection of Ezakiella genus in seminal samples. Two clusters of microbial profiles were built based on a clustering analysis, and specific genera were found with different frequencies in relation to seminal quality defects. The abundances of several bacteria negatively correlate with the sperm global DNA fragmentation, most notably Moraxella, Brevundimonas and Flavobacterium. The latter two were also associated with higher sperm motility and Brevundimonas additionally with lower oxidative-reduction potential. Actinomycetaceae, Ralstonia and Paenibacillus correlated with reduced chromatin protamination status and increased double-stranded DNA fragmentation. These effects on DNA integrity coincide in many cases with the metabolism or enzymatic activities of these genera. Significant differences between fertile and infertile men were found in the relative presence of the Propionibacteriaceae family and the Cutibacterium, Rhodopseudomonas and Oligotropha genera, which supports its possible involvement in male fertility. Our findings sustain the hypothesis that the seminal microbiome has an effect on male fertility.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Olmedo-Saura, Gonzalo|||0000-0003-4864-5548
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Epilepsy and Alzheimer's disease (AD) incidence increases with age. There are recip-rocal relationships between epilepsy and AD. Epilepsy is a risk factor for AD and, in turn, AD is an independent risk factor for developing epilepsy in old age, and abnormal AD biomarkers in PET and/or CSF are frequently found in late-onset epilepsies of unknown etiology. Accordingly, epilepsy and AD share pathophysiological processes, including neuronal hyperexcitability and an early excitatory-inhibitory dysregulation, leading to dysfunction in the inhibitory GABAergic and excitatory glutamatergic systems. Moreover, both β-amyloid and tau protein aggregates, the anato-mopathological hallmarks of AD, have proepileptic effects. Finally, these aggregates have been found in the resection material of refractory temporal lobe epilepsies, suggesting that epilepsy leads to amyloid and tau aggregates. Some epileptic syndromes, such as medial temporal lobe epilepsy, share structural and functional neuroimaging findings with AD, leading to overlapping symptomatology, such as episodic memory deficits and toxic synergistic effects. In this respect, the existence of epilepti-form activity and electroclinical seizures in AD appears to accelerate the progression of cognitive decline, and the presence of cognitive decline is much more prevalent in epileptic patients than in elderly patients without epilepsy. Notwithstanding their clinical significance, the diagnosis of clinical seizures in AD is a challenge. Most are focal and manifest with an altered level of consciousness without motor symptoms, and are often interpreted as cognitive fluctuations. Finally, despite the frequent association of epilepsy and AD dementia, there is a lack of clinical trials to guide the use of antiseizure medications (ASMs). There is also a potential role for ASMs to be used as disease-modifying drugs in AD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease

  • Benejam, Bessy|||0000-0002-6789-8615
  • Aranha, Mateus|||0000-0001-9594-292X
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Videla, Sebastián|||0000-0001-5049-1379
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Background: Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer's disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional brain atrophy in the population with Down syndrome has not been explored. We aimed to investigate the neuroanatomical correlates of episodic memory in adults with Down syndrome and symptomatic Alzheimer's disease. Methods: Single-center, cross-sectional study. A total of 139 adults with Down syndrome (85 asymptomatic and 54 with symptomatic Alzheimer's disease) were included in the study (mean age 43.6 ± 10.9 years, 46% female). Episodic memory was assessed using the modified Cued Recall Test. Immediate (trial 1 free immediate recall, trial 3 free immediate recall, total free immediate recall score, and total immediate score) and delayed scores (free delayed recall score and total delayed score) were examined. Cortical thickness from magnetic resonance imaging was determined with surface-based morphometry using the FreeSurfer 6.0 software package. The clusters of reduced cortical thickness were compared between symptomatic and asymptomatic participants to create a cortical atrophy map. Then, the correlation between cortical thickness and the modified Cued Recall Test subscores were separately assessed in symptomatic and asymptomatic subjects, controlling for age, sex, and severity of intellectual disability. Results: Compared with asymptomatic participants, those with symptomatic Alzheimer's disease showed a pattern of cortical atrophy in posterior parieto-temporo-occipital cortices. In symptomatic subjects, trial 1 immediate free recall significantly correlated with cortical atrophy in lateral prefrontal regions. Trial 3 free immediate recall and total free immediate recall were associated with the most widespread cortical atrophy. Total immediate score was related to posterior cortical atrophy, including lateral parietal and temporal cortex, posterior cingulate cortex, precuneus, and medial temporal lobe areas. Delayed memory scores were associated with cortical atrophy in temporoparietal and medial temporal lobe regions. No significant relationships were observed between episodic memory measures and cortical atrophy in asymptomatic subjects. Conclusions: Different episodic memory measures were associated with cortical atrophy in specific brain regions in adults with Down syndrome and Alzheimer's disease. These results overlap with those described in sporadic Alzheimer's disease and further support the similarities between Down syndrome-associated Alzheimer's disease and that in the general population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mendelian randomization analysis for attention deficit/hyperactivity disorder, studying a broad range of exposures and outcomes

  • Soler Artigas, María|||0000-0002-3213-1107
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Rovira, Paula|||0000-0003-2177-8412
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention deficit/hyperactivity disorder (ADHD) is a highly prevalent neurodevelopmental disorder caused by a combination of genetic and environmental factors and is often thought as an entry point into a negative life trajectory, including risk for comorbid disorders, poor educational achievement or low income. In the present study, we aimed to clarify the causal relationship between ADHD and a comprehensive range of related traits. We used genome-wide association study (GWAS) summary statistics for ADHD (n = 53 293) and 124 traits related to anthropometry, cognitive function and intelligence, early life exposures, education and employment, lifestyle and environment, longevity, neurological, and psychiatric and mental health or personality and psychosocial factors available in the MR-Base database (16 067 ≤ n ≤766 345). To investigate their causal relationship with ADHD, we used two-sample Mendelian randomization (MR) with a range of sensitivity analyses, and validated MR findings using causal analysis using summary effect estimates (CAUSE), aiming to avoid potential false-positive results. Our findings strengthen previous evidence of a causal effect of ADHD liability on smoking and major depression, and are consistent with a causal effect on odds of decreased average total household income [odds ratio (OR) = 0.966, 95% credible interval (CrI) = (0.954, 0.979)] and increased lifetime number of sexual partners [OR = 1.023, 95% CrI = (1.013, 1.033)]. We also found evidence for a causal effect on ADHD for liability of arm predicted mass and weight [OR = 1.452, 95% CrI = (1.307, 1.614) and OR = 1.430, 95% CrI = (1.326, 1.539), respectively] and time spent watching television [OR = 1.862, 95% CrI = (1.545, 2.246)], and evidence for a bidirectional effect for age of first sexual intercourse [beta = -0.058, 95% CrI = (-0.072, -0.044) and OR = 0.413, 95% CrI = (0.372, 0.457), respectively], odds of decreased age completed full-time education [OR = 0.972, 95% CrI = (0.962, 0.981) and OR = 0.435, 95% CrI = (0.356, 0.533), respectively] and years of schooling [beta = -0.036, 95% CrI = (-0.048, -0.024) and OR = 0.458, 95% CrI = (0.411, 0.511), respectively]. Our results may contribute to explain part of the widespread co-occurring traits and comorbid disorders across the lifespan of individuals with ADHD and may open new opportunities for developing preventive strategies for ADHD and for negative ADHD trajectories.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of Seminal Microbiome of Infertile Idiopathic Patients Using Third-Generation Sequencing Platform

  • Garcia Segura, Sergio|||0000-0001-9594-2938
  • Rey Azpiri, Javier del|||0000-0001-7887-7871
  • Closa, Laia|||0000-0001-8007-5077
  • García-Martinez, Iris|||0000-0001-6656-3322
  • Hobeich, Carlos
  • Castel, Ana Belén
  • Vidal, Francisco|||0000-0001-8089-4945
  • Benet i Català, Jordi|||0000-0001-6185-2555
  • Oliver Bonet, Maria|||0000-0001-5635-6741
Since the first description of a commensal seminal microbiome using sequencing, less than a decade ago, interest in the composition of this microbiome and its relationship with fertility has been growing. Articles using next-generation sequencing techniques agree on the identification of the most abundant bacterial phyla. However, at the genus level, there is still no consensus on which bacteria are most abundant in human seminal plasma. This discrepancy may be due to methodological variability such as sample collection, bacterial DNA extraction methodology, which hypervariable regions of 16S rRNA gene have been amplified, or bioinformatic analysis. In the present work, seminal microbiota of 14 control samples and 42 samples of idiopathic infertile patients were characterized based on full-length sequencing of the 16S rRNA gene using MinION platform from Oxford Nanopore. These same samples had been analyzed previously using Illumina's MiSeq sequencing platform. Comparison between the results obtained with the two platforms has been used to analyze the impact of sequencing method on the study of the seminal microbiome's composition. Seminal microbiota observed with MinION were mainly composed of the phyla Firmicutes, Proteobacteria, Bacteroidetes and Actinobacteria, with the most abundant genera being Peptoniphilus, Finegoldia, Staphylococcus, Anaerococcus, Campylobacter, Prevotella, Streptococcus, Lactobacillus, Ezakiella and Enterococcus. This composition was similar to that found by the Illumina platform, since these 10 most abundant genera were also among the most abundant genera detected by the Nanopore platform. In both cases, the top 10 genera represented more than 70% of the classified reads. However, relative abundance of each bacterium did not correlate between these two platforms, with intraindividual variations of up to 50 percentage points in some cases. Results suggest that the effect of the sequencing platform on the characterization of seminal microbiota is not very large at the phylum level, with slightly variances in Firmicutes and Actinobacteria, but presents differences at the genus level. These differences could alter the composition and diversity of bacterial profiles or posterior analyses. This indicates the importance of conducting multi-platform studies to better characterize seminal microbioma.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Nigro, Salvatore
  • Vandevrede, Lawren
  • Falgàs, Neus|||0000-0002-3404-2765
  • Heuer, Hilary W.
  • Painous, Cèlia|||0000-0002-7027-3093
  • Compta, Yaroslau|||0000-0001-6443-0104
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Montal, Victor|||0000-0002-5714-9282
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Logroscino, Giancarlo|||0000-0003-0423-3242
  • Quattrone, Andrea
  • Perry, David C.
  • Gorno-Tempini, Maria Luisa
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Grinberg, Lea T.
  • Spina, Salvatore
  • La Joie, Renaud
  • Rabinovici, Gil D.
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Rojas, Julio C.|||0000-0002-1308-646X
  • Seeley, William W.
  • Boxer, Adam
Importance: The accurate diagnosis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) is hampered by imperfect clinical-pathological correlations. Objective: To assess and compare the diagnostic value of the magnetic resonance parkinsonism index (MRPI) and other magnetic resonance imaging-based measures of cerebral atrophy to differentiate between PSP, CBD, and other neurodegenerative diseases. Design, Setting, and Participants: This prospective diagnostic study included participants with 4-repeat tauopathies (4RT), PSP, CBD, other neurodegenerative diseases and available MRI who appeared in the University of California, San Francisco, Memory and Aging Center database. Data were collected from October 27, 1994, to September 29, 2019. Data were analyzed from March 1 to September 14, 2021. Main Outcomes and Measures: The main outcome of this study was the neuropathological diagnosis of PSP or CBD. The clinical diagnosis at the time of the MRI acquisition was noted. The imaging measures included the MRPI, cortical thickness, subcortical volumes, including the midbrain, pons, and superior cerebellar peduncle volumes. Multinomial logistic regression models (MLRM) combining different cortical and subcortical regions were defined to discriminate between PSP, CBD, and other pathologies. The areas under the receiver operating characteristic curves (AUROC) and cutoffs were calculated to differentiate between PSP, CBD, and other diseases. Results: Of the 326 included participants, 176 (54%) were male, and the mean (SD) age at MRI was 64.1 (8.0) years. The MRPI showed good diagnostic accuracy for the differentiation between PSP and all other pathologies (accuracy, 87%; AUROC, 0.90; 95% CI, 0.86-0.95) and between 4RT and other pathologies (accuracy, 80%; AUROC, 0.82; 95% CI, 0.76-0.87), but did not allow the discrimination of participants with CBD. Its diagnostic accuracy was lower in the subgroup of patients without the canonical PSP-Richardson syndrome (PSP-RS) or probable corticobasal syndrome (CBS) at MRI. MLRM combining cortical and subcortical measurements showed the highest accuracy for the differentiation between PSP and other pathologies (accuracy, 95%; AUROC, 0.98; 95% CI, 0.97-0.99), CBD and other pathologies (accuracy, 83%; AUROC, 0.86; 95% CI, 0.81-0.91), 4RT and other pathologies (accuracy, 89%; AUROC, 0.94; 95% CI, 0.92-0.97), and PSP and CBD (accuracy, 91%; AUROC, 0.95; 95% CI, 0.91-0.99), even in participants without PSP-RS or CBS at MRI. Conclusions and Relevance: In this study, the combination of widely available cortical and subcortical measures of atrophy on MRI discriminated between PSP, CBD, and other pathologies and could be used to support the diagnosis of 4RT in clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of Alzheimer Disease with Life Expectancy in People with Down Syndrome

  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Garzón Chavez, Diana
  • Klitgaard Christensen, Maria
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Plana Ripoll, Oleguer|||0000-0002-6470-7465
  • Rasmussen, Sonja A.
  • Roqué i Figuls, Marta|||0000-0003-0043-1364
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Benejam, Bessy|||0000-0002-6789-8615
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Padilla, Concepción|||0000-0003-4102-6787
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Fernández, Susana|||0000-0002-9777-1156
  • Belbin, Olivia|||0000-0002-6109-6371
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fortea, Juan|||0000-0002-1340-638X
Importance: People with Down syndrome have a high risk of developing Alzheimer disease dementia. However, penetrance and age at onset are considered variable, and the association of this disease with life expectancy remains unclear because of underreporting in death certificates. Objective: To assess whether the variability in symptom onset of Alzheimer disease in Down syndrome is similar to autosomal dominant Alzheimer disease and to assess its association with mortality. Design, Setting, and Participants: This study combines a meta-analysis with the assessment of mortality data from US death certificates (n = 77347 case records with a International Classification of Diseases code for Down syndrome between 1968 to 2019; 37900 [49%] female) and from a longitudinal cohort study (n = 889 individuals; 46% female; 3.2 [2.1] years of follow-up) from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI). Main Outcomes and Measures: A meta-analysis was conducted to investigate the age at onset, age at death, and duration of Alzheimer disease dementia in Down syndrome. PubMed/Medline, Embase, Web of Science, and CINAHL were searched for research reports, and OpenGray was used for gray literature. Studies with data about the age at onset or diagnosis, age at death, and disease duration were included. Pooled estimates with corresponding 95% CIs were calculated using random-effects meta-analysis. The variability in disease onset was compared with that of autosomal dominant Alzheimer disease. Based on these estimates, a hypothetical distribution of age at death was constructed, assuming fully penetrant Alzheimer disease. These results were compared with real-world mortality data. Results: In this meta-analysis, the estimate of age at onset was 53.8 years (95% CI, 53.1-54.5 years; n = 2695); the estimate of age at death, 58.4 years (95% CI, 57.2-59.7 years; n = 324); and the estimate of disease duration, 4.6 years (95% CI, 3.7-5.5 years; n = 226). Coefficients of variation and 95% prediction intervals of age at onset were comparable with those reported in autosomal dominant Alzheimer disease. US mortality data revealed an increase in life expectancy in Down syndrome (median [IQR], 1 [0.3-16] years in 1968 to 57 [49-61] years in 2019), but with clear ceiling effects in the highest percentiles of age at death in the last decades (90th percentile: 1990, age 63 years; 2019, age 65 years). The mortality data matched the limits projected by a distribution assuming fully penetrant Alzheimer disease in up to 80% of deaths (corresponding to the highest percentiles). This contrasts with dementia mentioned in 30% of death certificates but is in agreement with the mortality data in DABNI (78.9%). Important racial disparities persisted in 2019, being more pronounced in the lower percentiles (10th percentile: Black individuals, 1 year; White individuals, 30 years) than in the higher percentiles (90th percentile: Black individuals, 64 years; White individuals, 66 years). Conclusions and Relevance: These findings suggest that the mortality data and the consistent age at onset were compatible with fully penetrant Alzheimer disease. Lifespan in persons with Down syndrome will not increase until disease-modifying treatments for Alzheimer disease are available.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cortical microstructure in primary progressive aphasia, a multicenter study

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Mandelli, Maria Luisa|||0000-0002-2518-2520
  • Falgàs, Neus|||0000-0002-3404-2765
  • Welch, Ariane E.
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Blesa, Rafael|||0000-0003-4026-2884
  • Dickerson, Bradford C.
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Lleó, Alberto|||0000-0002-2568-5478
  • Gorno-Tempini, Maria Luisa
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
Background: Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been proposed as a sensitive biomarker that might antedate macroscopic cortical changes. We aimed to test the hypothesis that cortical mean diffusivity is more sensitive than cortical thickness to detect cortical changes in primary progressive aphasia (PPA). Methods: In this multicenter, case-control study, we recruited 120 patients with PPA (52 non-fluent, 31 semantic, and 32 logopenic variants; and 5 GRN-related PPA) as well as 89 controls from three centers. The 3-Tesla MRI protocol included structural and diffusion-weighted sequences. Disease severity was assessed with the Clinical Dementia Rating scale. Cortical thickness and cortical mean diffusivity were computed using a surface-based approach. Results: The comparison between each PPA variant and controls revealed cortical mean diffusivity increases and cortical thinning in overlapping regions, reflecting the canonical loci of neurodegeneration of each variant. Importantly, cortical mean diffusivity increases also expanded to other PPA-related areas and correlated with disease severity in all PPA groups. Cortical mean diffusivity was also increased in patients with very mild PPA when only minimal cortical thinning was observed and showed a good correlation with measures of disease severity. Conclusions: Cortical mean diffusivity shows promise as a sensitive biomarker for the study of the neurodegeneration-related microstructural changes in PPA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients

  • Lennol, Matthew Paul
  • Sánchez-Domínguez, Irene|||0000-0001-6421-8293
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
  • Camporesi, Elena
  • Brinkmalm, Gunnar
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Soria, Guadalupe
  • Aguado, Fernando|||0000-0002-0393-1308
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Sáez-Valero, Javier
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Mitjans, M.
  • Hartman, CA.
  • Artigas, M. Soler
  • Demontis, Ditte|||0000-0001-9124-2766
  • Larsson, Henrik
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Kuntsi, J.
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Børglum, AD.
  • Reif, Andreas|||0000-0002-0992-634X
  • Franke, Barbara|||0000-0003-4375-6572
  • Cormand, Bru|||0000-0001-5318-4382
Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Gut microbiota signature in treatment-naïve attention-deficit/hyperactivity disorder

  • Richarte Fernández, Vanesa
  • Sanchez Mora, Cristina P
  • Corrales De la Cruz, Montserrat
  • Fadeuilhe Grau, Christian
  • Vilar Ribo, Laura
  • Arribas Garcia, Lorena
  • Garcia Gea, Estela
  • Rosales Ortiz, Silvia Karina
  • Soler Artigas, Maria
  • Ribases Haro, Marta
  • Ramos-Quiroga, Josep Antoni
TDAH; Comunitat científica, TDAH; Comunidad científica, ADHD; Scientific community, Compelling evidence supports alterations in gut microbial diversity, bacterial composition, and/or relative abundance of several bacterial taxa in attention-deficit/hyperactivity disorder (ADHD). However, findings for ADHD are inconsistent among studies, and specific gut microbiome signatures for the disorder remain unknown. Given that previous studies have mainly focused on the pediatric form of the disorder and involved small sample sizes, we conducted the largest study to date to compare the gastrointestinal microbiome composition in 100 medication-naïve adults with ADHD and 100 sex-matched healthy controls. We found evidence that ADHD subjects have differences in the relative abundance of several microbial taxa. At the family level, our data support a lower relative abundance of Gracilibacteraceae and higher levels of Selenomonadaceae and Veillonellaceae in adults with ADHD. In addition, the ADHD group showed higher levels of Dialister and Megamonas and lower abundance of Anaerotaenia and Gracilibacter at the genus level. All four selected genera explained 15% of the variance of ADHD, and this microbial signature achieved an overall sensitivity of 74% and a specificity of 71% for distinguishing between ADHD patients and healthy controls. We also tested whether the selected genera correlate with age, body mass index (BMI), or scores of the ADHD rating scale but found no evidence of correlation between genera relative abundance and any of the selected traits. These results are in line with recent studies supporting gut microbiome alterations in neurodevelopment disorders, but further studies are needed to elucidate the role of the gut microbiota on the ADHD across the lifespan and its contribution to the persistence of the disorder from childhood to adulthood.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • hartman, catharina
  • Larsson, Henrik
  • Ribases, Marta
  • Mitjans, Marina
  • Soler Artigas, María
  • Demontis, Ditte
  • Ramos-Quiroga, Josep Antoni
Trastorno por déficit de atención e hiperactividad; Comorbilidad; Genética de trastornos cruzados, Trastorn per dèficit d'atenció i hiperactivitat; Comorbiditat; Genètica de trastorns creuats, Attention-deficit/hyperactivity disorder; Comorbidity; Cross-disorder genetics, Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable., This research has received funding from the EU’s Horizon 2020 research and innovation program under grant agreements no. 667302 (CoCA), 728018 (Eat2beNICE) and 2020604 (TIMESPAN) and from the ECNP Network ‘ADHD across the Lifespan' (https://www.ecnp.eu/researchinnovation/ECNP-networks/List-ECNP-Networks/). B Cormand has also been supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-1277760B-I100), the Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas (PNSD-2017I050), Fundació La Marató de TV3 (202218-31), Generalitat de Catalunya/AGAUR (2021-SGR-1093), ICREA Academia 2021 and the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 841899 (GRASAD) and 101028810 (ATTENTIVE). M Ribasés was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE), by the Instituto de Salud Carlos III (PI20/00041, CP09/00119 and CPII15/00023), by the Pla estratègic de recerca i innovació en salut (PERIS), Generalitat de Catalunya (METAL-Cat; SLT006/17/287), by the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461) and by Fundació La Marató de TV3 (202228-30, 202228-31). JA Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE). M Mitjans was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD), the MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR” (RYC2021-033573-I), Ministerio de Ciencia e Innovación (PID2022-139740OA-100) and the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2021-SGR-1093). M Soler Artigas was supported by the Instituto de Salud Carlos III (P19/01224, PI22/00464 and CP22/00128) and by the European Regional Development Fund. B Franke and A Reif were also supported by funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME). B Franke also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011). D Demontis is supported by the Novo Nordisk Foundation (NNF20OC0065561 and NNF21SA0072102), the Lundbeck Foundation (R344-2020-1060), the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 965381 (TIMESPAN). AD Børglum was supported by the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003). Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any of the other funding organisations mentioned here.